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ABSTRACT 
Overcoming drug-resistance remains a key challenge to cure patients with acute and chronic 
B cell malignancies. Here we describe a stroma cell autonomous signaling pathway, which 
contributes to drug resistance of malignant B cells. We show that protein kinase C (PKC)--
dependent signals from bone marrow derived stroma cells markedly decrease the efficacy of 
cytotoxic therapies. Conversely, small molecule PKC- inhibitors antagonize pro-survival 
signals from stroma cells and sensitize tumor cells to targeted and non-targeted 
chemotherapy, leading to enhanced cytotoxicity and prolonged survival in vivo. 
Mechanistically, stromal PKC- controls the expression of adhesion- and matrix proteins, 
required for Phosphoinositide 3-kinases (PI3K) activation and the ERK-mediated 
stabilization of BCL-XL in tumor cells. Central to the stroma-mediated drug resistance is the 
PKC- dependent activation of transcription factor EB (TFEB), regulating lysosome 
biogenesis and plasma membrane integrity. Stroma directed therapies, enabled by direct 
inhibition of PKC-, enhance the effectiveness of many anti-leukemic therapies. 
 
SUMMARY 
Inhibition of stroma cell PKC- mitigates environment-mediated drug resistance in B cell 
malignancies. 
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INTRODUCTION 
Over the past decade next generation sequencing technologies provided opportunities to 
comprehensively describe the spectrum of genomic abnormalities found in various different 
B cell malignancies(1-4). Ultimately, this has improved our understanding of the underlying 
genetic mutations contributing to uncontrolled proliferation and extended cell survival while 
enabling the development of targeted therapies. Notably, drug resistance remains one of the 
most challenging clinical problems, reflected by the invariable disease recurrence of all low-
grade lymphoma-, chronic lymphocytic leukemia (CLL) patients and a substantial fraction of 
patients suffering from acute lymphoblastic leukemia and high-grade lymphoma. Thus, 
although a majority of patients achieve disease remissions, relapses occur from cells 
surviving cancer-therapies. Identifying and targeting cells, which have acquired properties to 
survive these treatments may ultimately allow to fully eradicate these tumor cells and to 
achieve cure. 
 
It has been recognized for some time that the tumor microenvironment plays a pivotal role 
for drug resistance by providing protective niches for tumor cells(5), allowing them to survive 
targeted and non-targeted therapies through the provision of anti-apoptotic signals. The 
bone marrow microenvironment appears to be of crucial importance for lymphoid diseases 
as minimal-residual disease detected in this compartment has a strong prognostic power to 
predict disease relapse in acute and chronic leukemia and lymphomas(6, 7). Several 
intermediates of the bone marrow microenvironment to tumor cell communications have 
been identified, but their targeting has been proven to be difficult and to result in minor 
effects at best (8),(9).  
Here we describe a stroma cell autonomous signaling pathway, dependent on the 
expression and activation of protein kinase C- (PKC-) and subsequent activation of the 
transcription factor EB, both being of key importance to protect malignant B cells from 
cytotoxic therapies. Importantly, the dependency of malignant B cells on PKC--activity in 
the microenvironment can be therapeutically exploited with small molecule inhibitors, to treat 
patients with different B cell malignancies, including CLL, mantle cell lymphoma (MCL) and 
B cell acute lymphoblastic leukemia (B-ALL).        
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RESULTS 
 
Stroma PKC- is essential for survival, but not homing or proliferation of TCL1-tg B 
cell tumors  
Our previous data demonstrated that PKC- activity in mesenchymal stroma cells (MSC) is 
essential for the engraftment of malignant B cells derived from Eμ-TCL1-tg mice(10), a 
model resembling human CLL(11). To further investigate the mechanisms underlying this 
phenotype, our experiments set out to characterize the role of stromal PKC- for tumor cell 
homing, proliferation and survival. Carboxyfluorescein-succinimidyl-ester(CFSE)- labeled 
CD5+CD19+ tumor cells from diseased TCL1-tg mice were transplanted intravenously (i.v.) 
and intraperitoneal (i.p.) into either PKC- knock out (KO) or wild-type (WT) recipient mice. 
In addition, malignant cells were transplanted into WT mice, which were pre-treated for 48 
hours with the PKC--inhibitor enzastaurin (60 mg/kg BID) or vehicle control and continued 
to receive treatment for 48 hours post-transplantation (fig. S1A). Tumor cells homed to the 
spleen and bone marrow of all recipient mice, irrespectively of PKC- expression in the 
microenvironment or its pharmacological inhibition (fig. S1, B and C). A separate cohort of 
PKC- KO and WT recipient mice was followed for 2 weeks and tumor engraftment was 
assessed in the peripheral blood, lymphatic tissues and the peritoneal cavity. A similar 
number of CFSE-labeled tumor cells were detectable in the peripheral blood of KO and WT 
mice on day 2. However, from day 8 onwards, we observed a marked increase of tumor 
cells in the peripheral blood of WT, but not in KO mice (fig. S1D). Two weeks after 
transplantation of tumor cells, malignant B cells were virtually absent in the bone marrow of 
KO mice and decreased in the spleen and peritoneal cavity of KO mice, in contrast to WT 
control mice where tumor cells were maintained (Fig. 1A and fig. S1E). During the first 2 
weeks, disease progression was more pronounced in the bone marrow, which showed a  
stronger dependency on PKC- compared to spleen or peritoneal cavity (Fig. 1B). The 
continuous decay of the CFSE-label with each cell division did not differ in KO and WT 
recipient mice (Fig. 1, C and D), indicating that PKC- expression in the tumor 
microenvironment is dispensable for tumor cell homing or proliferation but required to 
provide pro-survival factors, essential for engraftment and disease progression. 
 
PKC- expression in stroma cells is essential for tumor cell engraftment and normal 
B1 cell development 
We were then interested in investigating whether the lack of tumor cell engraftment in PKC- 
KO mice was entirely attributed to its absence in stroma cells or whether hematopoietic cells 
in the microenvironment also contributed. Germ-line deletion of PKC- in mice causes 
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immunodeficiency with a marked reduction of peritoneal B1 cells and a reduction in serum 
IgM and IgG3(12). Notably, no differences of white blood cells (WBC), hemoglobin or 
platelets were observed between WT and KO cells (fig. S2, A and B), also reflected by the 
presence of similar numbers of Lin-Sca1+C-Kit+ (LSK) and CD45+EPCR+CD150+CD48- 
(ESLAM) hematopoietic stem cells in the bone marrow (fig. S2C). In addition, the 
development of normal B cells was not affected by the germ-line deletion of PKC-, with B-
cell progenitor fractions (Hardy fractions A-D(13)) statistically similar between genotypes for 
both the frequency and absolute number of cells present per femur (fig. S2, D to F). 
By generating mixed chimeras, differing only in the expression of PKC- in the 
hematopoietic system, we could address whether the engraftment-dependence on 
microenvironment PKC- signals is due to the malignant transformation or reflects properties 
of the cell-of-origin. The cell-of-origin is thought to be a CD5+ B cell(14), in mouse most likely 
a CD5+ B1 cell, an innate type of B cell responsible for the production of natural antibodies. 
We generated PKC- chimeric mice by transplanting PKC- WT CD45+ hematopoietic bone 
marrow cells into lethally irradiated (10 Gy) KO animals. To allow for the assessment of 
chimerism WT CD45.1+ bone marrow cells were transplanted into CD45.2+ KO recipient 
mice. As controls, KO CD45.2+ BM cells were transplanted into CD45.1+ WT recipient mice 
(Fig. 1E and fig. S3A). Strikingly, in BM-reconstituted WT recipient animals we found no 
difference in the number of peritoneal B1 cells derived from either PKC- KO or WT donor 
cells. Conversely, the development of peritoneal B1 cells in KO recipient animals 
transplanted from WT bone marrow was significantly (p=0.02) reduced compared to WT 
recipient animals. Notably, the number of peritoneal B1 cells was still higher in these mice 
than in PKC- KO control recipients reconstituted with KO bone marrow (Fig. 1F and fig. 
S3B). Analogous to the germ-line deletion of PKC-, reconstitution of WT bone marrow in 
KO recipients was associated with reduced serum titers of the natural antibodies IgM and 
IgG3, whereas KO cells produced equivalent amounts of antibodies as WT cells in a WT 
background (Fig. 1G). These data demonstrate that PKC- is an important cell-extrinsic 
factor for B cell development. To assess whether the differences in serum IgM and IgG3 
titers were further associated with a PKC--dependent skewing of plasma cell differentiation, 
we compared chimerism of donor CD45+, CD138+ to donor CD45+, CD138- cells in the bone 
marrow and spleen. We found similar engraftment of either genotype in the bone marrow of 
PKC- WT and KO recipient animals with no differences between CD138+ and CD138- cells 
(fig. S3, D and E). PKC- WT donor cells also differentiated equally well in the spleens of 
either WT or KO recipient animals, whereas PKC- KO donor cells gave rise to fewer splenic 
CD45+ CD138+ cells in a WT background (fig. S3, D and F).  
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To address whether PKC- expressed in hematopoietic cells could rescue tumor cell 
survival in PKC- KO recipient animals, we injected TCL1-tumor cells into KO animals, 
previously transplanted with KO or WT CD45+ bone marrow cells (Fig. 1H). All recipient 
chimeric mice were deficient for PKC- in non-hematopoietic cells, but either did (WTKO) 
or did not (KOKO) contain PKC--expressing hematopoietic cells. Similar to our 
transplantation studies into non-chimeric mice, engraftment of tumor cells in the peripheral 
blood of WTKO animals compared to WT control mice was significantly (p=0.001) impaired 
(Fig. 1I and J). On the other hand, WTKO recipients contained only slightly more malignant 
cells than KOKO recipients, indicating that PKC--mediated survival signals by non-
hematopoietic cells play a predominant role in tumor maintenance. 
 
Inhibition of stromal PKC- mitigates environment-mediated drug resistance 
Signals derived from the microenvironment contribute not only to the development of normal 
hematopoietic cells, but also to drug resistance of malignant cells (termed environment-
mediated drug resistance; EMDR)(5). The marked dependency of malignant B cell survival 
on PKC- activity in the microenvironment raised the possibility that this interaction could be 
exploited therapeutically. To test this hypothesis, we cultured primary human CLL cells on 
bone marrow derived MSCs from either KO or WT mice. Notably, human MSCs were 
indistinguishable from mouse MSCs with regard to PKC- activation and survival 
support(10). In line with our previous observations, PKC- deficiency in bone marrow 
derived MSCs mitigated the anti-apoptotic effects of stromal cells on CLL cells (Fig. 2, A and 
B). To test the role of stromal PKC- in EMDR, parallel co-cultures were exposed 24 hours 
post-CLL seeding to increasing doses of venetoclax (BCL2-inhibitor), bendamustine 
(alkylating agent), fludarabine (purine analogue) or ibrutinib and idelalisib, (inhibitors of B-
cell receptor (BCR) - induced kinases), before assessing the viability of CLL cells 48 hours 
later. Expectedly, contact with WT MSCs enhanced the resistance of CLL cells to these 
cytotoxic drugs when compared to suspension cells in mono-culture (Fig. 2C). In particular, 
we observed strong protective effects of MCSs on CLL cells for venetoclax and fludarabine-
treatments, while EMDR to BCR-inhibitors was less pronounced. The absence of PKC- in 
MSCs completely abolished the protective effects seen with WT stromal cells under all 
treatments except for bendamustine, where PKC--deficiency nevertheless also strongly 
decreased stroma protection. Notably, PKC- expression in monocytes, which are derived 
from the hematopoietic system and also support leukemogenesis(15), was dispensable for 
response to cytotoxic therapies (fig. S4, A to D). These data indicate that PKC- expression 
in MSCs is crucial for EMDR of primary CLL cells.  
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We previously demonstrated that PKC- kinase activity in MSCs is essential for 
microenvironment-mediated survival support of leukemia cells(10). Therefore, we tested 
whether ablation of EMDR could be achieved with small molecule PKC-inhibitors. 
Enzastaurin and sotrastaurin are orally bioavailable, reversible ATP-competitive inhibitors of 
PKCs with enzastaurin being more specific for the -isoform (16, 17). Midostaurin is a multi-
kinase inhibitor with activity against PKC-isoforms and was recently approved for the 
treatment of FLT3-ITD+ AML(18). Co-cultures of WT MSCs and primary CLL cells were 
exposed to increasing low-doses of these inhibitors for 48 hours. Similar to co-culturing CLL 
cells on KO MSCs, each PKC-inhibitor reduced the viability of CLL cells (Fig. 2D). 
Importantly, the cytotoxic effects of enzastaurin and sotrastaurin did not exceed the survival-
disadvantage of KO MSCs and were dose-dependent, whereas midostaurin induced CLL 
cell death beyond this effect similarly across all doses. This suggests that midostaurin also 
inhibits other kinases in MSCs and/or has direct cytotoxic effects on primary CLL cells. To 
test whether PKC- inhibitors can sensitize malignant B cells to cytotoxic agents, we treated 
MSC/CLL-co-cultures for 48 hours with low dose (5 M) enzastaurin and increasing doses of 
different cytotoxic agents. Assessment of apoptotic CLL cells after 48 hours in co-culture 
indicated that enzastaurin sensitized CLL cells to venetoclax, bendamustine and fludarabine, 
pheno-copying the experiments with KO stromal cells (Fig. 2E; fig. S4, E and F; patient 
characteristics are provided in table S1), but not consistently to ibrutinib and idelalisib (fig. 
S4F). Using the Combenefit platform(19) for the assessment of drug-synergy, the Bliss-
independence and the Loewe-additivity models demonstrated that the cytotoxic effects of 
combinational treatments with venetoclax and PKC--inhibitors were indeed synergistic (Fig. 
2G and  fig. S4G). Similar to enzastaurin, the PKC-inhibitors sotrastaurin and midostaurin 
also chemo-sensitized malignant B cells to cytotoxic agents (Fig. 2G), indicating a class- 
rather than a drug-specific effect. 
Notably, PKC- expression is not restricted to MSCs, but also found at high amounts in 
malignant B cells(20). To prove that the synergistic effects are indeed mediated by the 
inhibition of stromal PKC- and not attributed to off-target effects or inhibition of PKC- 
expressed in tumor cells, we cultured primary CLL cells on PKC- KO stromal cells and then 
exposed co-cultures to enzastaurin in the absence or presence of venetoclax. Analyses of 
apoptotic B cells after 48 hours demonstrated that enzastaurin did not affect the survival of 
CLL cells cultured on PKC- KO stromal cells. Furthermore, under these conditions 
enzastaurin also did not enhance the cytotoxic effects of venetoclax (Fig. 2F). In conclusion, 
by genetically removing the target protein for the kinase inhibitor, these data prove that the 
PKC- inhibitor sensitizes malignant B cells to cytotoxic drugs by ablating microenvironment-
mediated, PKC--dependent survival signals and drug resistance. 
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The chemo-sensitizing effects of enzastaurin were most pronounced in combination with 
venetoclax. The efficacy of this BCL-2 inhibitor is largely dependent on the relative 
expression of other anti-apoptotic proteins. To understand how stromal PKC- inhibits the 
cytotoxicity of venetoclax, we analyzed the expression of anti-apoptotic proteins in CLL cells 
cultured either on WT or KO stromal cells. In CLL cells cultured on WT stromal cells and 
treated with a low-dose of venetoclax, BCL-XL was significantly (p=0.009 at 48 hours post-
treatment) up-regulated, whereas expression of BCL2, BCL2A1 and MCL-1 decreased after 
48 hours. In contrast to WT stromal cells, the enhanced expression of BCL-XL was markedly 
mitigated in CLL cells cultured on KO stromal cells (Fig. 2H, for protein-quantification see fig. 
S5A). Similar to co-culture on KO stromal cells, treatment of WT stroma-CLL co-cultures 
with venetoclax or other chemotherapies in combination with enzastaurin also blocked the 
up-regulation of BCL-XL in CLL cells (Fig. 2I). Notably, the stroma-dependent stabilization of 
BCL-XL was not regulated by enhanced transcription as BCL-XL transcripts were readily 
detectable in co-cultured CLL cells and remained stable following venetoclax treatment (fig. 
S5, B and C). In conclusion, the activation of PKC- in the microenvironment contributes to 
drug resistance by controlling the post-transcriptional regulation of BCL-XL in malignant B 
cells.   
 
Stromal PKC- is essential for ERK-activation and BCL-XL stabilization in CLL cells 
To further understand the role of stromal PKC- in EMDR, RNA-seq expression profiling was 
performed on primary CLL cells cultured on either WT or KO stroma in the presence of 
venetoclax (used at a minimal concentration of 1.25 nM to avoid substantial cell death (see 
Fig. 2C)). Clustering of the global expression changes between conditions demonstrate a 
considerable difference in the CLL response to venetoclax when co-cultured with WT versus 
KO stroma (Fig. 3A). Pairwise comparison of gene expression in CLL cells cultured on either 
WT or KO stroma in the presence of venetoclax identified 810 differentially expressed genes 
(DEG); of these, 755 were significantly up-regulated in CLL cells cultured on WT stroma 
compared to cells co-cultured on KO stroma, while 55 genes were down-regulated (adjusted 
p-value <0.01; log2 fold-change >1). Gene set enrichment analysis indicates that co-culture 
on WT stromal cells enhanced the expression of genes required for ECM-remodeling and 
cell-cell interactions (Fig. 3B and data file S1). We then used Ingenuity Pathway Analysis 
(IPA) to identify canonical pathways and regulators operating up-stream of these 
transcriptional changes. These analyses indicated that PI3K and MAPK signaling was 
inhibited in CLL cells cultured on KO stroma (Fig. 3C) associated with effects on integrin- 
and TGF- pathways (fig. S6A). Indeed, immunoblot analysis showed ERK-, but not p38- or 
JNK-pathway activation in CLL cells cultured on WT stroma under venetoclax exposure. 
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This activation was severely mitigated in venetoclax-treated tumor cells cultured on KO 
stromal cells (Fig. 3D, fig. S6B) or cultured on WT stroma in the presence of enzastaurin (fig. 
S6C). Notably, ERK-activation was associated with enhanced BCL-XL expression, 
suggesting a functional link between the two. Indeed, the MEK1/2-inhibitor Trametinib 
antagonized venetoclax induced ERK-activation, and was associated with decreased BCL-
XL protein expression (Fig. 3E) and enhanced cytotoxicity (Fig. 3F).  
Since activation of PI3K has been shown to limit the efficacy of venetoclax (21, 22), we 
investigated whether the PI3K inhibitor idelalisib also synergized with venetoclax in inducing 
apoptosis in CLL cells. Indeed, in combination with the PI3K inhibitor, venetoclax-induced 
apoptosis was enhanced (Fig. 3G) and AKT-phosphorylation, used as a surrogate to assess 
PI3K activity in malignant B cells, was abolished (Fig. 3H). To distinguish between idelalisib-
effects in tumor or stroma cells, we performed immunoblotting from CLL cells cultured in the 
presence of venetoclax on either WT or KO stroma cells.  Results from this experiment 
indicated that PI3K is activated in venetoclax treated tumor cells and that stroma PKC-β 
activity contributes to this activation, though this dependency was less pronounced than 
effects observed on MAPK-signaling (Fig. 3I and fig. S6D). 
To provide further evidence that the up-regulation of PKC-β-mediated and EMDR-associated 
genes has clinical relevance, we retrospectively assessed the impact of stroma-mediated, 
de-regulated pathways on progression-free and overall survival in a cohort of fludarabine-
refractory CLL patients(23).  Co-expression of genes in CLL, regulated by stroma PKC-, 
was found as a signature in a majority of the drug-resistant cohort (Fig. 3J). Moreover, 
patients with high co-expression signatures demonstrated a worse prognosis to salvage 
treatment, compared to low-expression signature patients (Fig. 3K and fig. S6E), 
emphasizing the relevance of these genes, identified in co-culture, to clinical 
observations.  Conclusively, our in vitro data show that stroma-mediated drug resistance to 
venetoclax is mediated by ERK- and PI3K-signaling, dependent on PKC- activity in stromal 
cells.  
 
PKC- dependent lysosome biogenesis is required for EMDR of B cells 
These results prompted us to also investigate the molecular events orchestrated by PKC- 
in stromal cells. RNA sequencing analysis was performed using PKC- WT and KO stromal 
cells co-cultured with primary CLL cells for 48 hours. A total of 3,352 genes with significantly 
changed expression (fold-change >2; adjusted p-value <0.05) were identified in PKC- KO 
cells, compared with WT cells (Fig. 4A). This demonstrates a broad impact of PKC- on 
stromal cell characteristics, including stark differences in the expression of genes encoding 
plasma membrane- and intracellular vesicular proteins.  Nearly half of all annotated plasma 
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membrane and intracellular vesicular protein genes were differentially regulated between 
PKC- WT and KO stroma, with 438 and 287 genes exhibiting greater than a two-fold 
change in either gene set, respectively (adjusted p-value <0.05). Gene set enrichment 
analysis (GSEA) revealed PKC- WT stromal enrichment of genes involved in ECM 
interactions and lysosome vesicle biogenesis (Fig. 4, B and C). Analysis of lysosome 
biogenesis by lysosome staining showed a substantially reduced lysosomal content in PKC-
 KO cells compared to WT stroma (fig. S7A). Moreover, PKC- KO stroma was also 
resistant to chloroquine-induced lysosome accumulation compared to WT stroma.  In line 
with our observations, lysosome biogenesis in osteoclasts has been shown to be controlled 
by PKC- mediated serine phosphorylation of the transcription factor EB (TFEB) C-terminal 
motif(24). Phosphorylation of TFEB increased its nuclear abundance and enhanced 
transcriptional activity (25). 
TFEB is a member of the MiT-TFE family of transcription factors, which are major factors 
regulating lysosome biogenesis and autophagy (26). To ascertain whether lysosome 
deregulation extended to stroma in co-culture with CLL under stress conditions, 
immunoblots for lysosome component protein, LAMP-1, and lysosome biogenesis 
transcription factor, TFEB, were conducted. Immunoblots showed markedly increased 
LAMP1 and TFEB protein expression in WT stroma at 24 and 48 hours, respectively, as 
compared to KO stroma in similarly treated CLL co-cultures (Fig. 4D). Further analysis found 
increased nuclear expression of TFEB in co-cultured PKC- WT compared to KO stroma 
(Fig. 4E and fig. S7B). To assess the importance of TFEB for stroma-mediated drug 
resistance, we generated TFEB deficient cells using CRISRP/Cas9 deletion (Fig. 4F). While 
TFEB deficient stroma cells and control counterparts provided equal survival support for 
primary CLL cells in the absence of drugs, exposure of co-cultures to venetoclax 
demonstrated that TFEB is an essential factor for EMDR (Fig. 4G). We used chloroquine 
and bafilomycin to interrogate whether the inhibition of lysosome function equally inhibits 
EMDR. Chloroquine-treated co-cultures did not show impaired survival of malignant B cells 
in contrast to bafilomycin, which reduced the anti-apoptotic effects from stroma on CLL cells. 
However, both compounds markedly enhanced the cytotoxic effects of venetoclax (Fig. 4H). 
To disentangle direct inhibitory effects of chloroquine and bafilomycin on CLL and stroma 
cells, stroma cells were pre-treated with both compounds before their washout, preceding 
primary CLL co-culture and subsequent venetoclax exposure. Pre-treatment of stroma cells 
similarly mitigated EMDR, indicating that the synergistic effects were attributed to the 
inhibition of stroma- and not CLL-lysosomes (fig. S7C). Lastly, complementary to the 
deletion of TFEB from stroma cells, parental KO stroma cells were transduced with a 
constitutively-active TFEB variant (caTFEB)(27) or vector control. CLL co-cultured with PKC-
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 KO stroma expressing caTFEB demonstrated a significantly (p=3.71E-07) higher 
resistance to venetoclax compared to cells cultured on control stroma (Fig. 4I and fig. S7D). 
Additionally, venetoclax exposed CLL cells, co-cultured on PKC- KO stroma expressing 
caTFEB, demonstrated increased amounts of BCL-XL and increased ERK-phosphorylation 
compared to CLL cells co-cultured on control KO stroma (Fig. 4J). To ascertain whether 
PKC- inhibition impairs in vivo lysosomal biogenesis, TCL1-transplanted recipient mice 
were treated with enzastaurin. Stroma-restricted down-regulation of both lysosomal-
associated membrane protein (LAMP)-1 and LAMP-2 was observed in the enzastaurin co-
treated cohort, in comparison to venetoclax-treated and vehicle control cohorts, respectively 
(Fig. 4K). In contrast, these lysosome-associated proteins were unchanged across all 
cohorts in the non-stroma compartment, signifying a stromal-specific response to PKC- 
inhibition in vivo. 
These data demonstrate that PKC- mediated activation of TFEB and lysosome biogenesis 
in stromal cells are central for EMDR and the reciprocal stabilization of BCL-XL in tumor 
cells. 
 
Plasma membrane protein composition of stromal cells is regulated by PKC- 
Our gene expression profiling of stroma cells indicates a disparate cell surface phenotype 
between PKC- WT and KO cells. To define the contribution of cell-cell interactions and 
response to venetoclax, we separated CLL cells from stromal cells using transwells. 
Disruption of cell-cell contact increased spontaneous apoptosis and venetoclax-induced cell 
death, indicating that cell-cell contact is of predominant importance for EMDR (Fig. 5A). To 
identify proteins on the surface of stromal cells relevant for contact-dependent survival of 
CLL cells, we performed plasma-membrane profiling (PMP) of MSCs, cultured in the 
absence or presence of CLL cells ± enzastaurin. Quantitative proteomic analysis identified 
changes in the composition of cell surface proteins of MSCs induced by contact with CLL 
cells (Fig. 5B and data file S2). Importantly, inhibition of PKC- with enzastaurin altered the 
expression of cell surface proteins of CLL-activated MSCs, whereby the amounts of 79 and 
123 proteins were up- and down-regulated by enzastaurin (q-value <0.05), respectively. A 
cluster of proteins with increased CLL-dependent cell surface expression was appreciably 
reduced by enzastaurin (cluster 2), whereas the surface expression of other proteins was 
increased after treatment with the PKC- inhibitor (clusters 1,3). Enzastaurin altered the 
expression of proteins that have potential roles in adhesion, including collagen1A2 and 
several matrix glycoproteins (Fig. 5C). In addition, surface proteins with a potential role for 
activating MSCs themselves were detected. The PKC- dependent expression of IL1Rl1, 
ADAM17 and IL6ST may contribute to the observed inflammatory gene signature of tumor-
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cell activated MSCs(10). Importantly, PMP of MSCs indicated that VCAM1 was also down-
regulated by enzastaurin. Flow cytometry analysis on primary MSCs from WT and KO mice 
demonstrated a significantly higher expression of VCAM1 on WT cells (Fig. 5D), which was 
down-regulated on CLL-activated stroma cells upon PKC- kinase inhibition (fig. S7E). 
VCAM1 can bind to integrins expressed on a variety of leukocytes, contributing to cell 
adhesion and survival (28). We therefore hypothesized that diminished EMDR observed in 
KO stromal cells was partly attributed to a reduced expression of VCAM1. To test this, we 
generated Vcam1-deficient bone marrow MSCs using CRISPR/Cas9. Assessment of 
viability of CLL cells, co-cultured on Vcam1 proficient or deficient stromal cells, indicated that 
VCAM1 contributes to the anti-apoptotic effects on malignant B cells. This dependency was 
further augmented by treatment with venetoclax (Fig. 5E). Similarly, a blocking antibody 
against VCAM1 enhanced spontaneous and venetoclax-induced apoptosis of CLL cells, 
indicating that VCAM1 is important for EMDR (Fig. 5F). Importantly, overexpression of 
constitutively active TFEB not only rescued EMDR (Fig. 4I), but also partially restored 
VCAM1 expression on KO cells (Fig. 5G). In support of this finding, deletion of TFEB caused 
a marked down-regulation of VCAM on stroma cells (Fig. 5H and fig. S7F), indicating that 
PKC--dependent activation of TFEB and lysosome biogenesis is important for plasma 
membrane integrity. 
As a number of adhesion molecules were impacted by enzastaurin, we investigated 
whether blocking PKC- resulted in a diminished capacity for adhesion of CLL cells in vitro. 
Patient CLL cells were flowed over PKC- WT and KO stroma in defined channel slides (fig. 
S8A). Results indicated no difference existed between the adhesive capacity of both stromal 
genotypes in this assay (Fig. 5I, blue), with both stroma able to retain flowing CLL cells 
comparably equally and concordant with the in vivo homing data previously observed. 
Subsequently, treatment of adhered CLL on WT stroma with either vehicle or enzastaurin, 
demonstrated no difference in CLL cells mobilized in comparison between enzastaurin 
treated and untreated conditions. Additionally, KO stroma also showed comparable number 
of mobilized CLL cells upon channel flushing (Fig. 5I, red), indicating reduced Vcam1 
expression does not impair stroma adhesion or retention of CLL under these conditions. To 
further validate this result, we treated diseased TCL1-tg mice for 2 consecutive days with 
enzastaurin before monitoring disease burden in the peripheral blood and lymphoid organs 
(Fig. 5J). In line with our in vitro data, we did not observe a mobilization of tumor cells into 
the peripheral blood. Likewise, disease burden in the peripheral blood, bone marrow, spleen 
and peritoneal cavity did not change over the course of the experiment (Fig. 5, K and L; fig. 
S8B and C). Notably, in vivo VCAM1 was markedly down-regulated on bone marrow derived 
CD45-Ter119- stroma cells from enzastaurin treated mice to similar amounts found on cells 
 13 
derived from KO mice (Fig. 5, M to O), indicating that the applied dose of enzastaurin was 
sufficient to inhibit stromal PKC- in vivo. VCAM1 expression on bone marrow MSCs may 
therefore be a suitable and easily accessible biomarker for drug-efficacy in future studies.  
In conclusion, our data show that PKC- kinase activity regulates the expression of 
numerous adhesion molecules on stromal cells. Their pharmacological down-regulation by 
kinase inhibitors does not affect positioning of malignant B cells within lymphoid niches but 
reduces EMDR. 
 
Enzastaurin enhances chemo-sensitivity and prolongs survival in vivo 
Encouraged by these results, we tested whether the chemo-sensitizing effects of PKC- 
inhibitors observed in vitro could be translated into the treatment of murine B cell 
malignancies. To this end, we transplanted 3.5 to 5x106 splenocytes from several individual, 
diseased TCL1-tg mice i.p. into 4 cohorts of syngeneic C57B/6 mice. Three days after 
transplantation, mice were orally treated for 16 consecutive days with either enzastaurin, 
venetoclax or a combination of both (treatment scheme is shown in  fig. S9A). Treatment 
was well tolerated without hematotoxicity (fig. S9B) or weight loss. However, venetoclax 
treated mice developed a loss of hair pigmentation, which was markedly enhanced with 
enzastaurin co-administration (fig. S9C). This is a known on-target side effect of venetoclax, 
explained by the exquisite dependency of melanoblasts on BCL-2(29). Monitoring of 
leukemogenesis in the peripheral blood revealed single agent treatment with enzastaurin or 
venetoclax, given over the course of 16 days, had no effect on the number of tumor cells in 
the peripheral blood or disease progression. In stark contrast, combination treatment 
reduced tumor burden and terminal spleen weights, whilst prolonging the life expectancy of 
mice (Fig. 6, A and B; fig. S9D). A separate assessment of BCL-XL in vivo in tumor cells of 
diseased animals showed that venetoclax induced its expression as anticipated from in vitro 
experiments (Fig. 6C). 
Similar to venetoclax, mice were also treated with fludarabine in combination with 
enzastaurin (fig. S9E). Disease progression, monitored in the peripheral blood 25-28 days 
after initial treatment, showed tumor cells in both cohorts with difference between treatment 
groups (32.4 ±3.4% of circulating tumor cells in the fludarabine group vs. 9.6% ±6.7% in the 
combination treatment group (fig. S9F)). Mice were then treated with a second cycle of 
therapy, 54 days after transplantation. The concurrent treatment of fludarabine and 
enzastaurin markedly prolonged survival of mice compared to fludarabine mono-therapy 
(Fig. 6D). No increased hematotoxicity was observed in mice concurrently treated with 
enzastaurin (fig. S9, G and H). 
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Our in vitro data demonstrated that the chemo-sensitizing effects of enzastaurin were 
ablated in co-cultures of tumor- and PKC- KO stroma cells, indicating that no off-target 
effects contributed to the enhanced cytotoxicity of venetoclax (Fig. 2F). To prove that no off-
target effects by co-administered enzastaurin contribute to the survival benefits observed in 
vivo, we generated TCL-1 driven B cell lymphoma which could overcome the strong 
dependency of Eμ-TCL1-tg cells on microenvironment PKC- (Fig. 1). Eμ-TCL1-tg mice 
were crossed onto transposon harboring mice expressing dual transposases PiggyBac and 
Sleeping Beauty (Hyper-GRONC, HG)(30, 31). Transplanted TCL1-HG tumors overcame 
loss of microenvironment PKC-, though displayed delayed leukemic progression compared 
to PKC- wild-type recipients receiving the same TCL1-HG cells (fig. S9I). After engraftment 
of B cell tumors from this mouse model in PKC- KO animals, mice were subsequently 
treated with venetoclax or a combination of enzastaurin and venetoclax. Venetoclax 
treatment prolonged life expectancy of diseased KO recipient mice. Importantly, the addition 
of enzastaurin did not result in extended survival (Fig. 6E), indicating that the chemo-
sensitizing effects of the PKC- inhibitor were not attributed to off-target effects or on-target 
inhibition of tumor-PKC-. 
Based on our previous observation that PKC- was also activated in stromal cells following 
contact to tumor cells from ALL and MCL patients(10), we investigated whether PKC- 
inhibition in WT stromal cells mitigated EMDR of co-cultured primary B cells from ALL and 
MCL patients. Analogous to CLL, enzastaurin enhanced the therapeutic effect of venetoclax 
on MCL cells (Fig. 6F and table S1). To demonstrate a chemo-sensitizing effect of PKC- 
inhibition on primary cells from ALL patients, enzastaurin was used in combination with 
dexamethasone or vincristine, both established chemotherapies in the treatment of ALL 
patients. Inhibition of stromal PKC- with enzastaurin increased the cytotoxicity of both 
drugs (Fig. 6G and table S1). Importantly, this effect was completely abolished in co-cultures 
with KO stromal cells (Fig. 6H), confirming that the PKC- inhibitor sensitized B-ALL cells by 
targeting stromal PKC- and excludes the contribution of off-target effects or inhibitory 
effects on PKC- expressed in ALL cells. To assess whether PKC- inhibition also 
sensitizes primary ALL cells to chemotherapy in vivo, NSG mice xenografted with luciferase-
labelled ALL-PDX cells were treated for 3 days with vincristine ± enzastaurin. 
Bioluminescent imaging between 3 to 6 weeks post-transplantation revealed comparable 
leukemic burdens between vehicle and enzastaurin-treated mice (Fig. 6I and fig. S9J). As 
expected from our in vitro data, enzastaurin mono-therapy did not extend survival of ALL 
xenografted mice compared to vehicle controls, while the concomitant administration of 
enzastaurin and vincristine  increased life-expectancy compared to single agent vincristine 
treatment (Fig. 6J).  
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In conclusion, enzastaurin increases the efficacy of different chemotherapy regimes in vivo 
by mitigating EMDR, demonstrated in pre-clinical CLL and ALL mouse models. In addition, 
ablation of EMDR by PKC- inhibition was also observed in another B cells malignancy in 
vitro, indicating that the inhibition of PKC--dependent EMDR sensitizes a broad range of B 
cell malignancies to cytotoxic therapies. 
 
DISCUSSION 
A growing amount of research has identified tumor-host interactions as essential processes 
regulating tumor cell immune evasion, metabolic adaptations, survival and proliferation (32). 
Here we describe a crucial dependency for survival of normal B1- and malignant B cells on 
PKC- expressed in stromal cells. Under conditions of cytotoxic stress PKC- regulates 
lysosome-biogenesis by stabilizing TFEB, which is essential for plasma membrane 
composition and EMDR, effectuated by BCL-XL expression in tumor cells. Genetic and 
pharmacological interference with this stress-response blunts this adaptation and increases 
the efficacy of chemotherapies (Fig. 7). 
Since neither homing nor proliferation of malignant B cells was affected by the removal of 
PKC- from the microenvironment, we hypothesize that the predominant role of stromal 
PKC- is the provision of survival signals to these cells that are intermittently required 
throughout their life-time. Under conditions of cytotoxic stress, PKC--dependent MAPK-
mediated up-regulation of BCL-XL is essential for drug resistance and cell survival. However, 
it remains to be experimentally addressed whether similar mechanisms are in place under 
steady-state conditions and if so, to define their temporal and spatial requirements. It 
appears that the bone marrow is of particular importance for malignant B cells as the 
absence of PKC- leads to a rapid loss of adoptively transferred cells in this compartment.  
This is in consonance with the clinical importance of this compartment for many B cells 
diseases, as reflected by the negative impact of bone marrow minimal-residual-disease 
(MRD)-positivity on progression-free-survival (7, 33). However, this conclusion is partly 
based on a lack of data, since MRD assessment in patients is restricted to easily accessible 
locations. Therefore, it remains unknown whether chemo-protective niches exist in other 
organs. While we have observed the strongest dependency on PKC- in the bone marrow 
compartment during early disease stages, it is reasonable to assume that the spatial 
requirements and cellular composition of drug-protective niches are dynamic and change 
over time. In support of this hypothesis, in the Eμ-TCL-1 model the spleen appears to be the 
predominant site of disease at a terminal stage. The marked reduction of the spleen size in 
enzastaurin co-treated mice suggests that drug-protective niches also exist in this organ and 
are possibly more relevant at later disease stages. Indeed, we found that splenic follicular 
 16 
reticular cells (FRCs) can mediate PKC- dependent drug resistance in vitro, similar to 
MSCs (fig S10A). Therefore, cell types other than bone marrow MSCs, present in different 
organs, are likely to also contribute to the observed effects in vivo. Their identification and 
molecular characterization is important and can be achieved through the employment of 
reporter mice. 
 
In addition to tumor cells, we have observed that the physiological development of B1 cells 
also depends on PKC- activity in the microenvironment. Although predominantly derived 
from fetal liver progenitors, B1 cells can also be derived from bone marrow HSCs(34, 35). 
Results from our bone marrow chimeras, showing impaired B1 cell development of WT bone 
marrow cells in a PKC-β KO background were unexpected and, in light of previously 
published data, indicate that PKC- has a dual function in B cell development, maintenance 
and differentiation. Based on the observations made in germ-line deleted PKC- KO 
mice(12), several groups have unambiguously demonstrated that intrinsically expressed 
PKC- in B cells is essential for BCR-signaling through the recruitment of IKKs into lipid rafts 
and activation of IKK/ NF-B(36, 37). More recently, it was demonstrated that PKC- 
deficient B cells fail to present antigens and to differentiate into plasma cells upon 
immunization (38). However, the capacity to form germinal centers ex vivo was per se not 
ablated in PKC- KO B cells, indicating that the essential role of PKC- for B cell 
differentiation is dependent on cell-cell interactions. A dual function of PKC- in B cell 
physiology is also supported by our observation that WT bone marrow cells outperformed 
PKC- KO cells in KO recipient mice with respect to the development of peritoneal B1 cells. 
In surprising contrast, the capacity of KO cells to produce B1 cells was indistinguishable 
from WT cells in WT recipient animals. In line with this observation, we found similar titers of 
the natural antibodies IgM and IgG3 in WT recipient animals reconstituted with KO CD45+ 
bone marrow cells. Although we cannot fully exclude the possibility that plasma cells 
survived lethal irradiation of recipient mice(39) and contribute to these antibody 
concentrations, reduced IgM and IgG3 titers in KO recipient animals reconstituted with WT 
CD45+ bone marrow cells strongly suggest that extrinsically expressed PKC- is crucial for 
the production of natural antibodies. These findings reveal that the exquisite dependence of 
malignant B cells, especially under therapy, on PKC-β-dependent functions in their 
environment is already an integral part of normal B cell physiology.  
 
Central to the environment-mediated drug resistance observed in our studies was a PKC-β-
mediated increase in BCL-XL expression, in response to various chemotherapeutics with 
differing mechanisms of drug action. It was previously recognized that BCL-XL can confer a 
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multi-drug resistant phenotype in hematopoietic- (40) and non-hematopoietic cells (41), 
making it a key target for therapy. Interestingly, CLL cells respond to the cellular stress of 
BCL-2 antagonism by a microenvironment-mediated post-transcriptional increase in BCL-XL 
expression. However, our data show that the increased BCL-XL protein expression in CLL 
co-cultured with PKC-β WT stroma was not attributed to enhanced transcription. This raises 
questions about the underlying mechanisms causing an extrinsically-mediated increase of 
BCL-XL protein. Different post-translational modifications of BCL-XL, such as 
ubiquitination(42) and deamidation(43), must also be considered as possible contributing 
factors.  
BCL-XL was reported to be critical for the escape of self-reactive B-cells from negative 
selection: Self-reactive B-cells with enforced BCL-XL expression were shown to have some 
hallmarks of receptor editing and were uniformly anergic, after central deletion escape (44). 
The correlative ERK1/2 activation we experimentally observed in CLL cells may also be 
indicative of an anergic program, which has been reported to favor survival(45, 46). We may 
speculate though that the cellular stress of BCL-2 inhibition could re-invoke a 
microenvironment-mediated anergic survival program previously utilized by self-reactive B-
cells to escape central deletion. In line with this speculation Eμ-TCL1 cells that failed to 
engraft in PKC-β-deficient mice might have failed to increase BCL-XL expression in vivo and 
succumbed to a retained autoimmunity checkpoint invoked by the absence of extrinsic PKC-
β. Notwithstanding the exact physiological counterpart, we clearly demonstrate MEK1/2- or 
PKC-β inhibition represent very clinically attractive approaches to mitigate EMDR by 
preventing the up-regulation of BCL-XL in the malignant cells. 
 
Our experiments demonstrate that VCAM1 expression on stromal cells is exquisitely 
dependent on PKC-β-mediated activation of TFEB. Previous studies have reported that the 
acute deletion of Vcam1 in adult mice led to a reduction of immature and mature B cells in 
the bone marrow (47, 48). In addition, homing of adoptively transferred mature B cells to the 
bone marrow was significantly impaired in these mice(47). In contrast, germ-line deletion of 
Vcam1, though is very often embryonic lethal, gave rise to a hypomorphic mouse model with 
no defects in B cell maturation (49), suggesting that low expression of VCAM1 is sufficient 
for B cell development or that compensatory mechanisms exist. It is reasonable to assume 
that the reduced expression of VCAM1 on bone marrow MSCs of PKC-β-deficient mice 
contributes to the PKC-β-deficient phenotypes. The low expression of constitutive VCAM1 
on mesenchymal cells of PKC-β KO mice is possibly related to reduced activity of NF-B, as 
Vcam1 is a direct transcriptional target(50). We have previously demonstrated the PKC-β 
dependent activation of NF-B in stromal cells, essential for tumor cell survival, is dependent 
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on Essential Modulator (NEMO)(10). Here we describe that the PKC-β dependent activation 
of TFEB and resultant lysosome biogenesis is of critical importance for plasma membrane 
composition and EMDR. Therefore, it is reasonable to speculate that the NF-B deficiency 
observed in PKC-β KO stromal cells is, at least partially, attributed to a lack of lysosome-
mediated degradation of IB, as previously described(51, 52). However, lysosomes are 
multi-functional organelles, contributing to many cellular processes, including autophagy, 
exosome release, plasma membrane repair and adhesion. Therefore, other mechanisms 
may operate in parallel, including ECM-remodeling and enhanced integrin-signaling(53, 54), 
which could both further contribute to EMDR.   
We believe that we have generated sufficient data to justify investigating the chemo-
sensitizing properties of PKC-β inhibitors in a clinical setting. We have observed substantial 
survival benefits by co-administered enzastaurin in all our in vivo treatment experiments: Of 
note, our treatment with venetoclax was limited to 16 days. It can be expected that a 
continuous treatment with PKC-β inhibitors and venetoclax, as it is clinical practice in 
patients, will provide much greater survival benefits and deeper remissions. Similarly, the 
extended survival observed with combination treatment in our ALL-PDX model is a proof-of-
principle that PKC-β inhibitors enhance the cytotoxic effects of vincristine. In contrast to the 
treatment of ALL patients, which receive cytotoxic therapies for 1-2 years, diseased animals 
received only a very short course of vincristine, which already lead to a substantial survival 
benefit. Enhanced effects of PKC-β inhibitors are therefore likely to be observed in clinical 
practice with repeated treatment cycles given to patients. 
Conceptually similar to our proposed drug combinations, the concomitant treatment with 
BCL-2- and BTK-inhibitors is currently being investigated in lymphoma patients(55), aiming 
at blocking microenvironment interactions to enhance the cytotoxicity of venetoclax. 
Contrary to this concept, our data indicate that PKC-β inhibitors cause an “in-situ chemo-
sensitization” of B cells as we have not observed an adherence-deficiency or a redistribution 
of cells into the peripheral blood upon kinase inhibition. The reduced expression of adhesion 
molecules on PKC-β deficient stromal cells likely reduces survival signals to leukemic cells, 
but without affecting niche residency. The dependency of different types of B cells, including 
normal B1 cells and immature malignant B cells, on PKC-β functions in the 
microenvironment, further indicates that PKC-β inhibitors may be clinically used beyond the 
spectrum of BCR-inhibitor sensitive disease entities. The treatment of auto-immune 
diseases with a pathogenic contribution from B cells, such as systemic lupus erythematous, 
may also benefit from the chemo-sensitizing effects of PKC-β inhibitors.  
At present, the PKC-β inhibitor enzastaurin, an oral ATP-competitive small molecule inhibitor 
with a relative specificity for PKC-β(16), is in clinical development at the stage of phase III 
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trials (e.g. NCT03263026). In addition, midostaurin, though less specific for the β-isoform, 
has recently been approved for the treatment of AML patients (18). Based on the 
observation that PKC-β is intrinsically expressed in malignant B cells, favorable phase II 
data and an excellent safety profile, the PRELUDE phase III trial was designed to test the 
efficacy of enzastaurin as maintenance mono-therapy for DLBCL patients in at least partial 
remission following treatment with R-CHOP. The trial failed its primary end point (disease 
free survival)(56), which led to a temporary halt in the clinical development of the drug. 
Notably, contrary to low-grade lymphomas or ALL, MRD is clinically not a problem for the 
vast majority of DLBCL patients, suggesting that EMDR may not play a substantial role for 
the majority of patients with high-grade NHL. This is reflected by the observation that 70% of 
patients in the PRELUDE trial were already cured at the end of immuno-chemotherapy, 
before commencing maintenance therapy. 
Our data provide evidence that the chemo-sensitizing effects of enzastaurin depend on the 
lysosome-mediated remodeling of cell-surface and matrix-proteins. Since enzastaurin 
undergoes liver-mediated degradation and has a short half-life(57), contributing to a 
substantial inter-subject variability in the steady-state plasma concentration(58), we predict 
that the timing between administering a PKC-β inhibitor to mitigate EMDR and cytotoxic 
agents are important for their synergism. Biomarkers such as VCAM1 or LAMP1 expression 
in MSCs should therefore be used in future clinical trials to determine the optimal time 
between co-administering chemo-sensitizing- and cytotoxic therapy. 
The incorporation of PKC-β inhibitors in treatment-regimens used for various B cells 
malignancies may have profound clinical and socioeconomic implications: improved clinical 
responses may ultimately allow for the reduction of the number of treatment cycles, lowering 
cumulative drug doses and minimizing side effects, costs and need for salvage therapies. 
Notably our data demonstrate that the application of PKC-β inhibitors can be limited to 
treatment days, minimizing their compound-specific side effects and costs. Clinical trials are 
now needed to address whether our data can be translated into improved patient care.      
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MATERIAL AND METHODS 
 
STUDY DESIGN 
Our primary objective was to test whether the dependency of malignant B cells from patients 
with CLL, MCL and ALL patients on PKC-β expressed and activated in the tumor 
microenvironment could be harnessed therapeutically. By transferring normal bone marrow 
or labeled tumor cells into WT and KO recipient mice we demonstrate that stroma PKC-β is 
required for normal B1 cell development and the survival of malignant B cells. This 
dependency was further investigated through ex vivo co-culture experiments, in which we 
demonstrate that small molecule inhibitors targeting PKC-β mitigate environment mediated 
drug resistance by blocking the up-regulation of BCL-XL in tumor cells in an ERK and PI3K 
dependent manner. We employed RNAseq and mass spectrometry to delineate the 
molecular mechanisms in stromal cells, demonstrating that stromal PKC-β is essential for 
the activation of TFEB. Activated TFEB in stromal cells regulates the expression of adhesion 
molecules required for stroma-mediated protection from cytotoxic agents. Our data were 
validated through in vivo experiments, in which diseased C57B/6 or NSG- mice were treated 
with cytotoxic agents in combination with PKC-β inhibitors.  
We did not use statistics to predetermine sample sizes. Animals were randomly assigned to 
genotypes or the 4 treatment cohorts (vehicle control, venetoclax or vincristine, enzastaurin, 
enzastaurin + venetoclax or vincristine). Sample sizes in the mouse experiments were based 
on own and published data (10, 59). Animal wellbeing was monitored daily and all 
experiments were conducted under the UK Home Office regulations. Investigators were not 
blinded to treatment allocations, but animal technicians who delivered care and decided 
independently upon which animals needed to be sacrificed (applying strict criteria for end 
points) were blinded. In vitro studies were conducted with multiple technical and biological 
replicates to ensure reproducibility of data. 
 
STATISTICAL ANALYSES 
All in vitro experiments were repeated at least three times, and the means ± SEM were 
calculated. The exact sample size for each experiment is provided in the figure legends. 
Statistical analyses of results were performed using one-way ANOVA followed by two-tail 
Student t-tests, with respective unpaired and paired analyses experimentally dependent. 
Statistical annotations as previously noted were denoted with asterisks according to the 
following, ****p < 0.0001, *** p <0.001, **p<0.01, *p<0.05, and ns p >0.05. In vivo studies 
were carried out using multiple animals (3 to 15 per group, specified in figures), and Kaplan-
Meier curves were generated from survival data. 
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SUPPLEMENTARY MATERIALS 
 
Material and Methods 
Figure S1: Homing and engraftment kinetics of E-TCL1 CLL in PKC- wild-type and null 
mice. 
Figure S2: PKC-deficiency does not overtly alter hematopoiesis. 
Figure S3: PKC- chimeras engraft with comparable efficiency irrespective of donor or 
recipient genotype. 
Figure S4: Monocytes confer CLL survival support but not PKC- dependent EMDR, in 
contrast to MSCs. 
Figure S5: PKC--mediated EMDR involves increased protein levels of BCL-XL. 
Figure S6: CLL signaling pathways regulated by stromal PKC- correlate with clinical 
outcomes. 
Figure S7: Stromal lysosomes, and lysosomal biogenesis regulator TFEB, are central to 
PKC--mediated EMDR. 
Figure S8: PKC- is dispensable for in vitro and in vivo mobilization of leukemia. 
Figure S9: In vivo co-targeting of PKC- does not contribute to increased off-target 
cytotoxicity. 
Figure S10: EMDR derived from splenic stroma is mitigated by PKC- antagonism. 
Figure S11: Representative FACS gating strategies. 
Table S1: Patient characteristics. 
Table S2: Key resources. 
Data File S1: Excel file of top deregulated genes from CLL RNA-Seq in Fig.3C 
Data File S2: Excel file of proteomic clusters from Fig. 5B,C. 
Data File S3: Excel file of individual data from experiments with n<20 per group. 
References (60-68) 
 
 
 
 
 
 
 
 
 
 
 22 
 
REFERENCES AND NOTES 
1. X. S. Puente, M. Pinyol, V. Quesada, L. Conde, G. R. Ordóñez, N. Villamor, G. 
Escaramis, P. Jares, S. Beà, M. González-Díaz, L. Bassaganyas, T. Baumann, M. Juan, M. 
López-Guerra, D. Colomer, J. M. C. Tubío, C. López, A. Navarro, C. Tornador, M. Aymerich, 
M. Rozman, J. M. Hernández, D. A. Puente, J. M. P. Freije, G. Velasco, A. Gutiérrez-
Fernández, D. Costa, A. Carrió, S. Guijarro, A. Enjuanes, L. Hernández, J. Yagüe, P. 
Nicolás, C. M. Romeo-Casabona, H. Himmelbauer, E. Castillo, J. C. Dohm, S. de Sanjosé, 
M. A. Piris, E. de Alava, J. San Miguel, R. Royo, J. L. Gelpí, D. Torrents, M. Orozco, D. G. 
Pisano, A. Valencia, R. Guigó, M. Bayés, S. Heath, M. Gut, P. Klatt, J. Marshall, K. Raine, L. 
A. Stebbings, P. A. Futreal, M. R. Stratton, P. J. Campbell, I. Gut, A. López-Guillermo, X. 
Estivill, E. Montserrat, C. López-Otín, E. Campo, Whole-genome sequencing identifies 
recurrent mutations in chronic lymphocytic leukaemia, Nature 475, 101–105 (2011). 
2. V. Quesada, L. Conde, N. Villamor, G. R. Ordóñez, P. Jares, L. Bassaganyas, A. J. 
Ramsay, S. Beà, M. Pinyol, A. Martínez-Trillos, M. López-Guerra, D. Colomer, A. Navarro, 
T. Baumann, M. Aymerich, M. Rozman, J. Delgado, E. Giné, J. M. Hernández, M. González-
Díaz, D. A. Puente, G. Velasco, J. M. P. Freije, J. M. C. Tubío, R. Royo, J. L. Gelpí, M. 
Orozco, D. G. Pisano, J. Zamora, M. Vázquez, A. Valencia, H. Himmelbauer, M. Bayés, S. 
Heath, M. Gut, I. Gut, X. Estivill, A. López-Guillermo, X. S. Puente, E. Campo, C. López-
Otín, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in 
chronic lymphocytic leukemia, Nat. Genet. 44, 47–52 (2012). 
3. B. Chapuy, C. Stewart, A. J. Dunford, J. Kim, A. Kamburov, R. A. Redd, M. S. Lawrence, 
M. G. M. Roemer, A. J. Li, M. Ziepert, A. M. Staiger, J. A. Wala, M. D. Ducar, I. Leshchiner, 
E. Rheinbay, A. Taylor-Weiner, C. A. Coughlin, J. M. Hess, C. S. Pedamallu, D. Livitz, D. 
Rosebrock, M. Rosenberg, A. A. Tracy, H. Horn, P. van Hummelen, A. L. Feldman, B. K. 
Link, A. J. Novak, J. R. Cerhan, T. M. Habermann, R. Siebert, A. Rosenwald, A. R. Thorner, 
M. L. Meyerson, T. R. Golub, R. Beroukhim, G. G. Wulf, G. Ott, S. J. Rodig, S. Monti, D. S. 
Neuberg, M. Loeffler, M. Pfreundschuh, L. Trümper, G. Getz, M. A. Shipp, Molecular 
subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic 
mechanisms and outcomes, Nat. Med. 24, 679–690 (2018). 
4. R. Schmitz, G. W. Wright, D. W. Huang, C. A. Johnson, J. D. Phelan, J. Q. Wang, S. 
Roulland, M. Kasbekar, R. M. Young, A. L. Shaffer, D. J. Hodson, W. Xiao, X. Yu, Y. Yang, 
H. Zhao, W. Xu, X. Liu, B. Zhou, W. Du, W. C. Chan, E. S. Jaffe, R. D. Gascoyne, J. M. 
Connors, E. Campo, A. López-Guillermo, A. Rosenwald, G. Ott, J. Delabie, L. M. Rimsza, K. 
Tay Kuang Wei, A. D. Zelenetz, J. P. Leonard, N. L. Bartlett, B. Tran, J. Shetty, Y. Zhao, D. 
R. Soppet, S. Pittaluga, W. H. Wilson, L. M. Staudt, Genetics and Pathogenesis of Diffuse 
Large B-Cell Lymphoma, N. Engl. J. Med. 378, 1396–1407 (2018). 
5. M. B. Meads, R. A. Gatenby, W. S. Dalton, Environment-mediated drug resistance: a 
major contributor to minimal residual disease, Nat. Rev. Cancer 9, 665–674 (2009). 
6. D. A. Berry, S. Zhou, H. Higley, L. Mukundan, S. Fu, G. H. Reaman, B. L. Wood, G. J. 
Kelloff, J. M. Jessup, J. P. Radich, Association of Minimal Residual Disease With Clinical 
Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis, JAMA 
Oncol 3, e170580–e170580 (2017). 
7. S. Böttcher, M. Ritgen, K. Fischer, S. Stilgenbauer, R. M. Busch, G. Fingerle-Rowson, A. 
M. Fink, A. Bühler, T. Zenz, M. K. Wenger, M. Mendila, C.-M. Wendtner, B. F. Eichhorst, H. 
Döhner, M. J. Hallek, M. Kneba, Minimal residual disease quantification is an independent 
predictor of progression-free and overall survival in chronic lymphocytic leukemia: a 
multivariate analysis from the randomized GCLLSG CLL8 trial, J. Clin. Oncol. 30, 980–988 
 23 
(2012). 
8. B. Löwenberg, W. van Putten, M. Theobald, J. Gmür, L. Verdonck, P. Sonneveld, M. Fey, 
H. Schouten, G. de Greef, A. Ferrant, T. Kovacsovics, A. Gratwohl, S. Daenen, P. Huijgens, 
M. Boogaerts, Dutch-Belgian Hemato-Oncology Cooperative Group, Swiss Group for 
Clinical Cancer Research, Effect of priming with granulocyte colony-stimulating factor on the 
outcome of chemotherapy for acute myeloid leukemia, N. Engl. J. Med. 349, 743–752 
(2003). 
9. G. J. Ossenkoppele, G. Stussi, J. Maertens, K. van Montfort, B. J. Biemond, D. Breems, 
A. Ferrant, C. Graux, G. E. de Greef, C. J. M. Halkes, M. Hoogendoorn, R. M. Hollestein, M. 
Jongen-Lavrencic, M. D. Levin, A. A. van de Loosdrecht, M. van Marwijk Kooij, Y. van 
Norden, T. Pabst, H. C. Schouten, E. Vellenga, G. E. G. Verhoef, O. de Weerdt, P. 
Wijermans, J. R. Passweg, B. Löwenberg, Addition of bevacizumab to chemotherapy in 
acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian 
Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical 
Cancer Research (SAKK), Blood 120, 4706–4711 (2012). 
10. G. Lutzny, T. Kocher, M. Schmidt-Supprian, M. Rudelius, L. Klein-Hitpass, A. J. Finch, J. 
Dürig, M. Wagner, C. Haferlach, A. Kohlmann, S. Schnittger, M. Seifert, S. Wanninger, N. 
Zaborsky, R. Oostendorp, J. Ruland, M. Leitges, T. Kuhnt, Y. Schäfer, B. Lampl, C. Peschel, 
A. Egle, I. Ringshausen, Protein kinase c-β-dependent activation of NF-κB in stromal cells is 
indispensable for the survival of chronic lymphocytic leukemia B cells in vivo, Cancer Cell 
23, 77–92 (2013). 
11. R. Bichi, S. A. Shinton, E. S. Martin, A. Koval, G. A. Calin, R. Cesari, G. Russo, R. R. 
Hardy, C. M. Croce, Human chronic lymphocytic leukemia modeled in mouse by targeted 
TCL1 expression, Proc. Natl. Acad. Sci. U.S.A. 99, 6955–6960 (2002). 
12. M. Leitges, C. Schmedt, R. Guinamard, J. Davoust, S. Schaal, S. Stabel, A. 
Tarakhovsky, Immunodeficiency in protein kinase cbeta-deficient mice, Science 273, 788–
791 (1996). 
13. R. R. Hardy, K. Hayakawa, B cell development pathways, Annu. Rev. Immunol. 19, 595–
621 (2001). 
14. M. Seifert, L. Sellmann, J. Bloehdorn, F. Wein, S. Stilgenbauer, J. Dürig, R. Küppers, 
Cellular origin and pathophysiology of chronic lymphocytic leukemia, J. Exp. Med. 209, 
2183–2198 (2012). 
15. M. Seiffert, A. Schulz, S. Ohl, H. Döhner, S. Stilgenbauer, P. Lichter, Soluble CD14 is a 
novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is 
induced by CLL cells in vitro and present at abnormally high levels in vivo, Blood 116, 4223–
4230 (2010). 
16. M. M. Faul, J. R. Gillig, M. R. Jirousek, L. M. Ballas, T. Schotten, A. Kahl, M. Mohr, 
Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta, 
Bioorg. Med. Chem. Lett. 13, 1857–1859 (2003). 
17. J. Wagner, P. von Matt, R. Sedrani, R. Albert, N. Cooke, C. Ehrhardt, M. Geiser, G. 
Rummel, W. Stark, A. Strauss, S. W. Cowan-Jacob, C. Beerli, G. Weckbecker, J.-P. 
Evenou, G. Zenke, S. Cottens, Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-
yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein 
kinase C isotypes, J. Med. Chem. 52, 6193–6196 (2009). 
 24 
18. R. M. Stone, S. J. Mandrekar, B. L. Sanford, K. Laumann, S. Geyer, C. D. Bloomfield, C. 
Thiede, T. W. Prior, K. Döhner, G. Marcucci, F. Lo-Coco, R. B. Klisovic, A. Wei, J. Sierra, M. 
A. Sanz, J. M. Brandwein, T. de Witte, D. Niederwieser, F. R. Appelbaum, B. C. Medeiros, 
M. S. Tallman, J. Krauter, R. F. Schlenk, A. Ganser, H. Serve, G. Ehninger, S. Amadori, R. 
A. Larson, H. Döhner, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a 
FLT3 Mutation, N. Engl. J. Med. 377, 454–464 (2017). 
19. G. Y. Di Veroli, C. Fornari, D. Wang, S. Mollard, J. L. Bramhall, F. M. Richards, D. I. 
Jodrell, Combenefit: an interactive platform for the analysis and visualization of drug 
combinations, Bioinformatics 32, 2866–2868 (2016). 
20. D. El-Gamal, K. Williams, T. D. LaFollette, M. Cannon, J. S. Blachly, Y. Zhong, J. A. 
Woyach, E. Williams, F. T. Awan, J. Jones, L. Andritsos, K. Maddocks, C.-H. Wu, C.-S. 
Chen, A. Lehman, X. Zhang, R. Lapalombella, J. C. Byrd, PKC-β as a therapeutic target in 
CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL, Blood 124, 1481–1491 
(2014). 
21. K. Bojarczuk, K. Wienand, J. A. Ryan, L. Chen, M. Villalobos-Ortiz, E. Mandato, J. 
Stachura, A. Letai, L. N. Lawton, B. Chapuy, M. A. Shipp, Targeted inhibition of PI3Kα/δ is 
synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL, Blood 133, 70–
80 (2019). 
22. G. S. Choudhary, S. Al-Harbi, S. Mazumder, B. T. Hill, M. R. Smith, J. Bodo, E. D. Hsi, 
A. Almasan, MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can 
be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies, Cell 
Death Dis 6, e1593–e1593 (2015). 
23. S. Stilgenbauer, T. Zenz, D. Winkler, A. Bühler, R. F. Schlenk, S. Groner, R. Busch, M. 
Hensel, U. Dührsen, J. Finke, P. Dreger, U. Jäger, E. Lengfelder, K. Hohloch, U. Söling, R. 
Schlag, M. Kneba, M. Hallek, H. Döhner, German Chronic Lymphocytic Leukemia Study 
Group, Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: 
clinical results and prognostic marker analyses from the CLL2H study of the German 
Chronic Lymphocytic Leukemia Study Group, J. Clin. Oncol. 27, 3994–4001 (2009). 
24. M. Ferron, C. Settembre, J. Shimazu, J. Lacombe, S. Kato, D. J. Rawlings, A. Ballabio, 
G. Karsenty, A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal 
biogenesis in osteoclasts, Genes Dev. 27, 955–969 (2013). 
25. Y. Li, M. Xu, X. Ding, C. Yan, Z. Song, L. Chen, X. Huang, X. Wang, Y. Jian, G. Tang, C. 
Tang, Y. Di, S. Mu, X. Liu, K. Liu, T. Li, Y. Wang, L. Miao, W. Guo, X. Hao, C. Yang, Protein 
kinase C controls lysosome biogenesis independently of mTORC1, Nat. Cell Biol. 18, 1065–
1077 (2016). 
26. Signals from the lysosome: a control centre for cellular clearance and energy 
metabolism, Nat. Rev. Mol. Cell Biol. 14, 283–296 (2013). 
27. N. P. Young, A. Kamireddy, J. L. Van Nostrand, L. J. Eichner, M. N. Shokhirev, Y. Dayn, 
R. J. Shaw, AMPK governs lineage specification through Tfeb-dependent regulation of 
lysosomes, Genes Dev. 30, 535–552 (2016). 
28. M. J. Elices, L. Osborn, Y. Takada, C. Crouse, S. Luhowskyj, M. E. Hemler, R. R. Lobb, 
VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site 
distinct from the VLA-4/fibronectin binding site, Cell 60, 577–584 (1990). 
29. S. Kamada, A. Shimono, Y. Shinto, T. Tsujimura, T. Takahashi, T. Noda, Y. Kitamura, H. 
 25 
Kondoh, Y. Tsujimoto, bcl-2 deficiency in mice leads to pleiotropic abnormalities: 
accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair 
hypopigmentation, and distorted small intestine, Cancer Res. 55, 354–359 (1995). 
30. G. S. Vassiliou, J. L. Cooper, R. Rad, J. Li, S. Rice, A. Uren, L. Rad, P. Ellis, R. 
Andrews, R. Banerjee, C. Grove, W. Wang, P. Liu, P. Wright, M. Arends, A. Bradley, Mutant 
nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice, 
Nat. Genet. 43, 470–475 (2011). 
31. M. J. Friedrich, L. Rad, I. F. Bronner, A. Strong, W. Wang, J. Weber, M. Mayho, H. 
Ponstingl, T. Engleitner, C. Grove, A. Pfaus, D. Saur, J. Cadiñanos, M. A. Quail, G. S. 
Vassiliou, P. Liu, A. Bradley, R. Rad, Genome-wide transposon screening and quantitative 
insertion site sequencing for cancer gene discovery in mice, Nat Protoc 12, 289–309 (2017). 
32. D. Hanahan, L. M. Coussens, Accessories to the crime: functions of cells recruited to the 
tumor microenvironment, Cancer Cell 21, 309–322 (2012). 
33. N. Gökbuget, M. Kneba, T. Raff, H. Trautmann, C.-R. Bartram, R. Arnold, R. Fietkau, M. 
Freund, A. Ganser, W.-D. Ludwig, G. Maschmeyer, H. Rieder, S. Schwartz, H. Serve, E. 
Thiel, M. Brüggemann, D. Hoelzer, German Multicenter Study Group for Adult Acute 
Lymphoblastic Leukemia, Adult patients with acute lymphoblastic leukemia and molecular 
failure display a poor prognosis and are candidates for stem cell transplantation and 
targeted therapies, Blood 120, 1868–1876 (2012). 
34. B. L. Esplin, R. S. Welner, Q. Zhang, L. A. Borghesi, P. W. Kincade, A differentiation 
pathway for B1 cells in adult bone marrow, Proc. Natl. Acad. Sci. U.S.A. 106, 5773–5778 
(2009). 
35. S. Düber, M. Hafner, M. Krey, S. Lienenklaus, B. Roy, E. Hobeika, M. Reth, T. Buch, A. 
Waisman, K. Kretschmer, S. Weiss, Induction of B-cell development in adult mice reveals 
the ability of bone marrow to produce B-1a cells, Blood 114, 4960–4967 (2009). 
36. T. T. Su, B. Guo, Y. Kawakami, K. Sommer, K. Chae, L. A. Humphries, R. M. Kato, S. 
Kang, L. Patrone, R. Wall, M. Teitell, M. Leitges, T. Kawakami, D. J. Rawlings, PKC-beta 
controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling, 
Nat. Immunol. 3, 780–786 (2002). 
37. K. Saijo, I. Mecklenbräuker, A. Santana, M. Leitger, C. Schmedt, A. Tarakhovsky, 
Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective 
regulation of the IkappaB kinase alpha, J. Exp. Med. 195, 1647–1652 (2002). 
38. C. Tsui, N. Martinez-Martin, M. Gaya, P. Maldonado, M. Llorian, N. M. Legrave, M. 
Rossi, J. I. MacRae, A. J. Cameron, P. J. Parker, M. Leitges, A. Bruckbauer, F. D. Batista, 
Protein Kinase C-β Dictates B Cell Fate by Regulating Mitochondrial Remodeling, Metabolic 
Reprogramming, and Heme Biosynthesis, Immunity (2018), 
doi:10.1016/j.immuni.2018.04.031. 
39. J. J. Miller, L. J. Cole, The radiation resistance of long-lived lymphocytes and plasma 
cells in mouse and rat lymph nodes, J. Immunol. 98, 982–990 (1967). 
40. A. J. Minn, C. M. Rudin, L. H. Boise, C. B. Thompson, Expression of bcl-xL can confer a 
multidrug resistance phenotype, Blood 86, 1903–1910 (1995). 
41. S. A. Amundson, T. G. Myers, D. Scudiero, S. Kitada, J. C. Reed, A. J. Fornace, An 
informatics approach identifying markers of chemosensitivity in human cancer cell lines, 
 26 
Cancer Res. 60, 6101–6110 (2000). 
42. R. Kajihara, H. Sakamoto, K. Tanabe, K. Takemoto, M. Tasaki, Y. Ando, S. Inui, Protein 
phosphatase 6 controls BCR-induced apoptosis of WEHI-231 cells by regulating 
ubiquitination of Bcl-xL, J. Immunol. 192, 5720–5729 (2014). 
43. B. E. Deverman, B. L. Cook, S. R. Manson, R. A. Niederhoff, E. M. Langer, I. Rosová, L. 
A. Kulans, X. Fu, J. S. Weinberg, J. W. Heinecke, K. A. Roth, S. J. Weintraub, Bcl-xL 
deamidation is a critical switch in the regulation of the response to DNA damage, Cell 111, 
51–62 (2002). 
44. W. Fang, B. C. Weintraub, B. Dunlap, P. Garside, K. A. Pape, M. K. Jenkins, C. C. 
Goodnow, D. L. Mueller, T. W. Behrens, Self-reactive B lymphocytes overexpressing Bcl-xL 
escape negative selection and are tolerized by clonal anergy and receptor editing, Immunity 
9, 35–45 (1998). 
45. B. Apollonio, C. Scielzo, M. T. S. Bertilaccio, E. Ten Hacken, L. Scarfò, P. Ranghetti, F. 
Stevenson, G. Packham, P. Ghia, M. Muzio, F. Caligaris-Cappio, Targeting B-cell anergy in 
chronic lymphocytic leukemia, Blood 121, 3879–88– S1–8 (2013). 
46. M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-
Cappio, P. Ghia, Constitutive activation of distinct BCR-signaling pathways in a subset of 
CLL patients: a molecular signature of anergy, Blood 112, 188–195 (2008). 
47. C. E. Leuker, M. Labow, W. Müller, N. Wagner, Neonatally induced inactivation of the 
vascular cell adhesion molecule 1 gene impairs B cell localization and T cell-dependent 
humoral immune response, J. Exp. Med. 193, 755–768 (2001). 
48. P. A. Koni, S. K. Joshi, U. A. Temann, D. Olson, L. Burkly, R. A. Flavell, Conditional 
vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone 
marrow, J. Exp. Med. 193, 741–754 (2001). 
49. C. Friedrich, M. I. Cybulsky, J. C. Gutierrez-Ramos, Vascular cell adhesion molecule-1 
expression by hematopoiesis-supporting stromal cells is not essential for lymphoid or 
myeloid differentiation in vivo or in vitro, Eur. J. Immunol. 26, 2773–2780 (1996). 
50. H. B. Shu, A. B. Agranoff, E. G. Nabel, K. Leung, C. S. Duckett, A. S. Neish, T. Collins, 
G. J. Nabel, Differential regulation of vascular cell adhesion molecule 1 gene expression by 
specific NF-kappa B subunits in endothelial and epithelial cells, Mol. Cell. Biol. 13, 6283–
6289 (1993). 
51. A. M. Cuervo, W. Hu, B. Lim, J. F. Dice, IkappaB is a substrate for a selective pathway 
of lysosomal proteolysis, Mol. Biol. Cell 9, 1995–2010 (1998). 
52. L.-Y. Chu, Y.-C. Hsueh, H.-L. Cheng, K. K. Wu, Cytokine-induced autophagy promotes 
long-term VCAM-1 but not ICAM-1 expression by degrading late-phase IκBα, Sci Rep 7, 
12472 (2017). 
53. V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel, C. Peters, D. Hanahan, J. A. 
Joyce, Distinct roles for cysteine cathepsin genes in multistage tumorigenesis, Genes Dev. 
20, 543–556 (2006). 
54. L. Akkari, V. Gocheva, J. C. Kester, K. E. Hunter, M. L. Quick, L. Sevenich, H.-W. Wang, 
C. Peters, L. H. Tang, D. S. Klimstra, T. Reinheckel, J. A. Joyce, Distinct functions of 
macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor 
 27 
malignancy via interactions with the extracellular matrix, Genes Dev. 28, 2134–2150 (2014). 
55. C. S. Tam, M. A. Anderson, C. Pott, R. Agarwal, S. Handunnetti, R. J. Hicks, K. Burbury, 
G. Turner, J. Di Iulio, M. Bressel, D. Westerman, S. Lade, M. Dreyling, S.-J. Dawson, M. A. 
Dawson, J. F. Seymour, A. W. Roberts, Ibrutinib plus Venetoclax for the Treatment of 
Mantle-Cell Lymphoma, N. Engl. J. Med. 378, 1211–1223 (2018). 
56. M. Crump, S. Leppa, L. Fayad, J. J. Lee, A. Di Rocco, M. Ogura, H. Hagberg, F. Schnell, 
R. Rifkin, A. Mackensen, F. Offner, L. Pinter-Brown, S. Smith, K. Tobinai, S.-P. Yeh, E. D. 
Hsi, T. Nguyen, P. Shi, M. Hahka-Kemppinen, D. Thornton, B. Lin, B. Kahl, N. Schmitz, K. J. 
Savage, T. Habermann, Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus 
Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse 
Large B-Cell Lymphoma, J. Clin. Oncol. 34, 2484–2492 (2016). 
57. P. A. Welch, V. P. Sinha, A. L. Cleverly, C. Darstein, S. D. Flanagan, L. C. Musib, 
Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of 
enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects, J Clin 
Pharmacol 47, 1138–1151 (2007). 
58. M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. 
Sullivan, J. Riddle, J. Schmidt, N. Enas, V. Sinha, D. E. Thornton, R. S. Herbst, Phase I 
dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta 
inhibitor, in patients with advanced cancer, J. Clin. Oncol. 24, 4092–4099 (2006). 
59. N. L. M. Liem, R. A. Papa, C. G. Milross, M. A. Schmid, M. Tajbakhsh, S. Choi, C. D. 
Ramirez, A. M. Rice, M. Haber, M. D. Norris, K. L. MacKenzie, R. B. Lock, Characterization 
of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of 
new therapies, Blood 103, 3905–3914 (2004). 
60. L. Wang, S. Wang, W. Li, RSeQC: quality control of RNA-seq experiments, 
Bioinformatics 28, 2184–2185 (2012). 
61. A. Dobin, C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. 
Chaisson, T. R. Gingeras, STAR: ultrafast universal RNA-seq aligner, Bioinformatics 29, 15–
21 (2013). 
62. S. Anders, P. T. Pyl, W. Huber, HTSeq--a Python framework to work with high-
throughput sequencing data, Bioinformatics 31, 166–169 (2015). 
63. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and  dispersion 
for RNA-seq data with DESeq2, Genome Biol. 15, 550 (2014). 
64. A. Sturn, J. Quackenbush, Z. Trajanoski, Genesis: cluster analysis of microarray data, 
Bioinformatics 18, 207–208 (2002). 
65. M. P. Weekes, S. Y. L. Tan, E. Poole, S. Talbot, R. Antrobus, D. L. Smith, C. Montag, S. 
P. Gygi, J. H. Sinclair, P. J. Lehner, Latency-associated degradation of the MRP1 drug 
transporter during latent human cytomegalovirus infection, Science 340, 199–202 (2013). 
66. E. J. Greenwood, N. J. Matheson, K. Wals, D. J. van den Boomen, R. Antrobus, J. C. 
Williamson, P. J. Lehner, Temporal proteomic analysis of HIV infection reveals remodelling 
of the host phosphoproteome by lentiviral Vif variants, Elife 5, 12112 (2016). 
67. R. Pan, L. J. Hogdal, J. M. Benito, D. Bucci, L. Han, G. Borthakur, J. Cortes, D. J. 
DeAngelo, L. Debose, H. Mu, H. Döhner, V. I. Gaidzik, I. Galinsky, L. S. Golfman, T. 
 28 
Haferlach, K. G. Harutyunyan, J. Hu, J. D. Leverson, G. Marcucci, M. Müschen, R. Newman, 
E. Park, P. P. Ruvolo, V. Ruvolo, J. Ryan, S. Schindela, P. Zweidler-McKay, R. M. Stone, H. 
Kantarjian, M. Andreeff, M. Konopleva, A. G. Letai, Selective BCL-2 inhibition by ABT-199 
causes on-target cell death in acute myeloid leukemia, Cancer Discov 4, 362–375 (2014). 
68. N. L. M. Liem, R. A. Papa, C. G. Milross, M. A. Schmid, M. Tajbakhsh, S. Choi, C. D. 
Ramirez, A. M. Rice, M. Haber, M. D. Norris, K. L. MacKenzie, R. B. Lock, Characterization 
of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of 
new therapies, Blood 103, 3905–3914 (2004). 
 
 
ACKNOWLEDGEMENTS  
We would like to express our deepest gratitude to patients who donated blood for research 
purposes. In particular, we thank Joanna Baxter and her team for enrolling patients in these 
studies. We would like to thank Anthony Green, Brian Huntly, George Vassiliou and Dan 
Hodson for scientific discussion. We are thankful for the generous provision of NestinGFP 
mice by Simon Mendez-Ferrer and the help of Claudia Korn for staining bone marrow 
sections. Eμ-TCL1-tg mice were kindly provided by Carlo Croce under an MTA.  
 
FUNDING 
This work was funded by Cancer Research UK (CRUK; C49940/A17480). I.R. is a senior 
CRUK fellow. M.S.S is supported by the DFG through SCHM2440/7-1 and CRC1243 (A12). 
L.G. & O.W. received funding from CWCUK (grant 14-169) and GOSHCC (grant V2617). 
A.E. receives research grants from the Austrian Science Fund (FWF; Transcan I2795-B28 to 
A.E. (FIRE-CLL), DACH grants I3282-B26 and I1299-B21 (FOR2036) and a grant from the 
Paracelsus Medical University (PMU Grant E-13/18/091-EGF). S.S. receives funding from 
the DFG (SFB1074 , project B1), relevant to this work. 
 
AUTHOR CONTRIBUTION 
E.P., J.C. and A.M. performed and analyzed experiments. S.F. analyzed all RNAseq and 
mass spectrometry data with support from J.R.B.. A.S. performed and analyzed HSC and 
progenitor populations in KO and WT mice (fig.S2). M.M., in collaboration with J.C.W. and 
P.J.L., performed the PMP experiment. H.S., A.E. and M.S.S. contributed conceptually to 
the project. V.E. and M.B. performed ALL-PDX experiments. Additionally, L.G. and O.W 
made a substantial contribution to carrying out the ALL-PDX studies and helped critique the 
output for important intellectual content. J.B. and S.S. provided data depicted in Fig. 3J and 
K; fig. S6E. Prkcb-KO mice were provided by M.L.; The manuscript was written by E.P., 
M.S.S. and I.R. 
 
 29 
 
COMPETING INTERESTS 
The authors declare to have no conflicts of interest. 
 
DATA AND MATERIAL AVAILABILITY 
The authors declare that the data supporting the findings of this study are available within 
the paper and its supplementary information. 
 
The gene expression profile data have been deposited in the GEO database under 
accession numbers GSE119808 (CLL RNA-Seq, Fig. 3) and GSE119813 (Stromal RNA-
seq, Fig. 4). 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119808 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119813  
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https://www.ebi.ac.uk/pride/archive/projects/PXD011062 
 
All other remaining data are available within the Article and Supplementary Files, or 
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FIGURE LEGENDS 
 
Fig. 1. Normal and malignant B1 cells require microenvironment PKC-for survival 
 
A. Quantification of CFSE-labeled E-TCL1 cells as a percentage total CD19
+
cells detected in 
respective tissues. Analyses are pooled from two independent experiments using two primary 
tumors. 
B. Ratios of mean percentage CFSE
+
 of CD19
+
 between Day 8 -14 to Day 2. 
C. Representative FACS histograms of various tissues, 2 and 14 days post-transplantation into 
respective PKC- WT and KO mice. Mean fluorescence intensity (MFI) of CFSE staining in 
CD19
+
 cells are noted alongside respective histograms. 
D. Quantification of CFSE MFI in CD19
+
 E-TCL1 cells detected in bone marrow, spleen, and 
peritoneal cavity of PKC- WT and KO mice. Analyses are pooled from two independent 
experiments using two primary tumors. 
E. An experimental schematic to assess the functional consequence of adoptive transfer of 
CD45
+
 selected PKC- WT BM or KO BM, respectively, into lethally-irradiated (10 Gy) PKC- 
WT or KO recipients. 
F. Non-irradiated WT control (n=3), WT:KO (n=7), and 4 individuals of WT:WT, WT:KO, and 
KO:KO were assessed for peritoneal CD19
+
CD5
+
IgM
+ 
cells with the label of donor cells in 
bold. Statistical significance was assessed using unpaired, two-tail Student t-tests. 
G. Assessed levels of serum immunoglobulins 9 weeks post-transplantation are shown with 
individual values representing the mean of duplicate measurements. Cohort means are 
shown with ±SEM. 
H. Schematic of secondary transplantation of E-TCL1 cells into PKC- chimeras. 
I. Representative flow cytometry plots of CFSE detection and CD19 staining from the peripheral 
blood of chimeras receiving TCL1-transplants. Chimeras are labelled with genotype of donor 
cells italicized and recipient genotype also indicated. 
J. Quantification of CFSE-labelled CD19
+
 E-TCL1 cells as a percentage total CD19
+ 
cells 
detected in the peripheral blood from E-TCL1 recipients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31 
 
 
 
Fig. 2. Stromal PKC- confers drug resistance to malignant B cells via BCL-XL expression 
 
A. Representative Annexin-V and DAPI stains of mono-cultured or respective co-cultured CLL 
cells, 72 hours post-seeding of CLL. 
B. Percentage of Live (Annexin V
-
, DAPI
-
), Annexin-V
+
, and Dead (DAPI
+
Annexin-V
+or-
) stained 
cells are shown for individually cultured primary CLL (n=7 unique patients) for the three 
culture-conditions. Statistical significance for live cells between conditions was assessed, 
using paired, two-tail Student t-tests. 
C. IC50 graphs of human CLL cells after 72 hours mono-culture, PKC- WT co-culture or PKC- 
KO co-culture, respectively, in the presence of venetoclax, bendamustine, fludarabine, 
ibrutinib or idelalisib treatment administered 24 hours post-seeding of CLL (n=5 patients per 
culture condition). CLL viabilities were normalized to respective DMSO controls. Statistical 
significance between PKC- WT and PKC- KO are shown. 
D. Annexin V
-
 measured viability of CLL cells (n=6) normalized to DMSO control, following 72 
hours after PKC- WT co-culture in the presence of increasing concentrations of enzastaurin, 
sotrastaurin, or midostaurin administered 24 hours post-seeding of CLL. Individual values 
from (b) are plotted for reference. 
E. Viability of CLL cells normalized to respective DMSO controls, following 72 hours PKC- WT 
co-culture with 48 hours of exposure to increasing doses of venetoclax (n=9; n=21 at 5nM 
dose) or fludarabine (n=9; n=8 at 100M dose) ± enzastaurin treatment.  
F. Linked graphs of patient CLL cell viability (n=7), in the presence of labeled treatments co-
cultured on PKC- KO stroma. Statistical significance was assessed using ratio-paired, two-
tail Student t-tests. 
G. Synergism was calculated using Combenefit Software (CRUK), within the Bliss model, for 
venetoclax combined with enzastaurin, sotrastaurin, or midostaurin, respectively (n=6). 
Heatmaps reflect assessment values noted for respective compound combinations, with error 
(±) indicated below. A scale of 50 to –50 is applied to values, with 50 representing maximal 
synergism and –50 being maximal antagonism. * p< 5× 10
-2
; ** p< 10
-3
; *** p< 10
-4
 
H. BCL2 family proteins and -Actin immunoblots of primary CLL at indicated time-points of 
venetoclax treatment, co-cultured with either PKC- WT stroma or PKC- KO stroma. 
I. BCL2 family proteins and -Actin immunoblots of primary CLL at indicated time-points of 
venetoclax, fludarabine, or bendamustine treatment, co-cultured with PKC- WT stroma ± 
enzastaurin. 
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Fig. 3. Stromal PKC- is essential for PI3K- and ERK-activation in CLL cells. 
 
A. Heat map of genes from co-cultured CLL cells after 24 hours of treatment. Purified CLL cells 
were harvested prior to RNA isolation (stroma contamination <1%). cDNA libraries were 
generated from purified mRNA, and sequencing was performed on Illumina's HiSeq 4000 to 
generate 50 bp single end (SE) reads. Unsupervised hierarchical clustering show genes that 
are differentially expressed in co-culture with either PKC- WT stroma or PKC- KO stroma, 
respectively, under vehicle treatment (left half of the map) or venetoclax treatment (right half 
of the map). Red and blue indicate relative high and low expression, respectively. Each 
condition analyzed depict three unique primary CLL samples.  
B. GSEA analysis evaluating canonical pathways enriched in CLL cells co-cultured with PKC- 
WT stroma. 
C. IPA (Qiagen NV) analysis of predicted upstream regulators of observed differential CLL 
expression based on computed activation z-score. 
D. BCL-XL, phosphorylated ERK (Thr202/Thr204), total ERK, phosphorylated JNK 
(Thr183/Thr185), phosphorylated p38 (Thr180/Tyr182) and -Actin immunoblots of primary 
CLL at indicated time-points of venetoclax treatment, co-cultured with either PKC- WT 
stroma or PKC- KO stroma. 
E. BCL-XL, phosphorylated ERK (Thr202/Thr204), total ERK and -Actin immunoblots of primary 
CLL under venetoclax treatment co-cultured with PKC- WT stroma ± trametinib (1 M). 
F. Viability of CLL cells (n=9) following 72 hours PKC- WT co-culture with 48 hours of exposure 
to venetoclax ± trametinib treatment. Annexin V
-
 measured viability of CLL cells normalized to 
DMSO controls. Statistical significance was assessed using a paired two-tail Student t-test. 
G. Annexin-V
 
measured CLL cell viability (n=5) following 72 hours PKC- WT co-culture with 48 
hours of exposure to venetoclax ± idelalisib treatment or ± enzastaurin treatment.  
H. Total AKT, phosphorylated AKT (T308), phosphorylated AKT (S473) and -Actin immunoblots 
of primary CLL under venetoclax treatment co-cultured with PKC- WT stroma ± idelalisib 
(7.5 M). 
I. Total AKT, phosphorylated AKT (T308), phosphorylated AKT (S473), BCL-XL, and -Actin 
immunoblots of primary CLL co-cultured with either PKC- WT stroma or PKC- KO stroma 
under venetoclax treatment. 
J. Heatmap displaying mRNA expression profiles of patient samples (n=51) after clustering of 6 
CLL-genes regulated by microenvironmental PKC-. Two major clusters, classified as gene 
signature “high co-expression” and “low co-expression”, segregate the cohort. 
K. Kaplan-Meier curves (x-axis with time since treatment) according to respective clusters (”High 
co-expression” vs. “Low co-expression”), showing statistically significant differences (pairwise 
log-rank tests) for median overall survival (OS) (”High co-expression”: 413 vs. “Low co-
expression”:1319 days; p<0.004). 
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Fig. 4. PKC- dependent lysosome biogenesis is central for stroma-mediated drug resistance. 
 
A. Differential gene expression between PKC- WT and KO stroma co-cultured with patient 
CLL cells (n=3) for 48 hours. The differentially expressed genes encoding plasma 
membrane and intracellular vesicle proteins are highlighted in blue and red, respectively. 
Significantly deregulated genes (p-adj <0.05, fold-change >2; 3,352 genes) were 
compared to the lists of annotated gene-sets for plasma membrane proteins (Protein 
Atlas; 1,734 genes) or intracellular vesicle genes (Gene Ontology Consortium; 1,259 
genes), respectively. 
B. GSEA analysis enrichment of canonical pathways associated with PKC- WT stroma co-
culture with patient CLL cells (n=3). 
C. Heatmap depicting differentially expressed genes between PKC- WT and KO from a 
Lysosomal Biogenesis geneset (Reactome).  
D. LAMP-1, TFEB and -Actin immunoblots of respective PKC- WT stroma and PKC- KO 
stroma, co-cultured with primary CLL under venetoclax treatment. 
E. Immunoblots of TFEB and TBP from respective nuclear lysates of PKC- WT stroma and 
PKC- KO stroma ± primary CLL co-culture. 
F. Immunoblot of TFEB for Tfeb-deleted stroma(sgRNA_3) and sgRNA control stroma and 
-Actin under CLL co-culture conditions. 
G. Linked viability plots of patient CLL cells (n=9) treated with vehicle or venetoclax under 
co-culture with PKC- WT control or Tfeb-deleted stroma.  
H. CLL viability assay (n=5) following 72 hours PKC- WT co-culture with 48 hours of 
exposure to enzastaurin, chloroquine, or bafilomycin ± venetoclax treatment. 
I. Linked viability plots of patient CLL cells (n=10) treated with vehicle or venetoclax under 
the respective co-culture conditions. Statistical significance was assessed using paired, 
two-tail Student t-tests. 
J. Immunoblots of BCL-XL, p-ERK, and -Actin of CLL co-cultured on either PKC- KO 
control or caTFEB transduced stroma ± venetoclax treatment. 
K. TCL1-transplanted PKC- WT recipients were treated with the indicated treatments 3 
days post-transplantation for the duration of 3 days. Bone marrow was subsequently 
analyzed for Lamp-1 and Lamp-2 expression in viable MSCs (CD45
-
Ter119
-
, left graph) 
and non-MSCs (CD45
+
Ter119
+
, right graph), with representative flow cytometry gating 
shown. Mean fluorescence intensity (MFI) of Lamp-1 and Lamp-2 are depicted for 
individual mice in both graphs, with statistical significance determined using an unpaired 
two-tail Student T-test. 
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Fig. 5. Stroma PKC-regulates plasma membrane integrity and VCAM1 expression 
 
A. Linked viability plots of CLL patient samples (n=11) ± Transwell sequestration in the 
presence of PKC- WT stroma, under respective vehicle or venetoclax treatment. CLL 
viabilities are normalized to respective DMSO controls. 
B. Global heatmap of plasma membrane proteins from PKC- WT stroma ± primary CLL co-
culture, treated with either vehicle or enzastaurin (5M), analyzed by mass spectrometry. 
The heatmap presents clustering of log2-transformed plasma membrane protein 
abundance for each of three replicates (k-means clustering; k=5), while the side plot 
depicts the mean protein abundance value for each treatment condition (maximum value 
of 225).  
C. Heatmap of significantly altered plasma membrane proteins on the surface of PKC- WT 
stroma co-cultured with CLL and treated with either vehicle or enzastaurin (5M) (q-
values <0.05).  
D. FACS histograms of Vcam1(CD106) expression on PKC- WT and PKC- KO stromal 
mono-cultures. 
E. Linked viability plots of CLL patient samples (n=10) normalized to respective DMSO 
controls, in the presence of PKC- WT stroma ± genetic deletion of Vcam1, under 
respective vehicle or venetoclax treatment. 
F. Linked viability plots of CLL patient samples (n=9) normalized to respective DMSO 
controls, in the presence of PKC- WT stroma ± Vcam1 neutralizing or control antibody, 
under respective vehicle or venetoclax treatment. 
G. FACS analysis of Vcam1 expression in CLL co-cultured on PKC- WT stroma with Crispr-
deleted cells transduced with sgRNA control or Tfeb-deleted stroma. 
H. FACS analysis of Vcam1 expression in PKC- WT and transduced PKC- KO stroma. 
I. Percentage plots of adhesion (blue) and mobilization (red) of CLL cells under the various 
indicated co-culture and treatment conditions. 
J. Experimental schematic to assess whether enzastaurin mobilizes CLL from leukemic E-
TCL1 mice. 
K. Graph of CD19
+
CD5
+
 cells in the peripheral blood of vehicle-treated E-TCL1 (n=4), 
enzastaurin-treated mice (n=5), and non-leukemic controls (n=4). 
L. Graph of CD19
+
CD5
+
 cells in the various noted compartments of vehicle-treated E-TCL1 
(n=4), enzastaurin-treated mice (n=5), and non-leukemic controls (n=4). 
M. Representative flow cytometry gating depicting bone marrow stromal cells (CD45
- 
Ter119
-
) assessed for Vcam1 expression in vivo. 
N. Representative FACS histograms of Vcam1 MFI from DAPI
-
CD45
-
Ter119
-
CD106
+ 
cells 
from bone marrow of E-TCL1 and PKC- KO mice. 
O. Graph of DAPI
-
CD45
-
Ter119
- 
CD106
 
MFI cells from bone marrow of indicated E-TCL1 
mice treated with vehicle (n=4), treated with enzastaurin (n=5), and PKC- KO mice 
(n=4). 
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Fig. 6. Enzastaurin enhances the therapeutic effects of chemotherapy in vivo  
 
A. Graphs of E-TCL1 CLL cells (CD5
+
B220
+
) in peripheral blood from treatment cohorts for 
the indicated post-transplantation timepoints. 
B. Kaplan–Meier survival curves of leukemic mice following vehicle therapy, respective 
single-agent therapies, and combined therapy of enzastaurin (60mg/kg) and venetoclax 
(100mg/kg) following IP injection of 2 respective E-TCL1 tumors. Statistical significance 
was determined using Log-rank (Mantel-Cox) analysis. Dosing scheme shown in fig. S9A. 
C. BCL-XL expression measured by flow cytometry as MFI of CD19
+
 splenocytes isolated 
from TCL1-engrafted wild-type mice treated for 72 hours with either vehicle (n=6) or 
venetoclax (n=7). 
D. Kaplan–Meier survival curves of leukemic mice following respective single-agent 
fludarabine therapy, and combined therapy of enzastaurin (60 mg/kg) and fludarabine (34 
mg/kg) following IP injection of 2 respective E-TCL1 tumors. Schematic of dosing shown 
in fig. S9E.  
E. PKC-–deficient (KO) mice received transplants of E-TCL1-HG splenocytes. Respective 
treatments began 72 hours post-transplantation, continuing for 3 days. Statistical 
significance was determined using Log-rank (Mantel-Cox) analysis. 
F. Linked viability graphs of primary MCL cells, normalized to respective DMSO controls, 
following co-culture with 48 hours of exposure to indicated doses of venetoclax (n=9) ± 
enzastaurin treatment. Statistical significance was assessed using a paired two-tail 
Student t-test. 
G. Linked viability graphs of primary ALL cells following 72 hours PKC- WT co-culture with 
48 hours of exposure to indicated doses of dexamethasone or vincristine (n=9) ± 
enzastaurin treatment. ALL viabilities were normalized to respective DMSO controls.  
H. Linked viability graphs of ALL cells, normalized to respective DMSO controls, following 72 
hours PKC- KO co-culture with 48 hours of exposure to indicated doses of 
dexamethasone or vincristine (n=5) ± enzastaurin treatment. 
I. Representative bioluminescent imaging of ALL-PDX engrafted NSG recipient mice from 
indicated treatment cohorts, 4 weeks post-transplantation. 
J. Kaplan-Meier curve of NSG engrafted ALL-PDX treatment cohorts from 3 independent 
experiments of 2 unique patient-derived xenografts (vehicle Control, MST= 69 days; 
enzastaurin-treated, MST= 69days; vincristine-treated, MST= 88 days; vincristine + 
enzastaurin-treated, MST= 101days). 
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Materials and Methods 
Primary cells and cell culture   
After informed patients’ consent and in accordance with the Helsinki declaration, 
peripheral blood was obtained from patients with a diagnosis of CLL, ALL, or MCL. 
Studies were approved by the local ethical committees of the Cambridgeshire Research 
Ethics Committee (07/MRE05/44), Technical University Munich (project number 
1894/07), and the Institutional Review Board of the Erasmus MC. Peripheral blood 
mononuclear cells (PBMC) were isolated from heparinized blood samples by 
centrifugation over a Ficoll-Hypaque layer (PAN-Biotech). Malignant B cells were 
harvested and cultured in RPMI 1640 (Gibco), supplemented with 10% fetal calf serum 
(FCS) penicillin/streptomycin 50 U/ml, sodium-pyruvate 1mM, L-glutamine 2 mM, L-
asparagine 20 mg/ml, 50 M 2-mercaptoethanol , 10mM HEPES  and MEM non-
essential amino acids (Gibco). All primary mouse bone marrow stromal cell cultures were 
cultured in MEM Alpha + GlutaMAX medium (ThermoFisher Scientific) supplemented 
with 10% fetal calf serum, 10% horse Serum (StemCell Technologies) 10 μM 2-
mercaptoethanol and 1% penicillin/streptomycin (Gibco). 
 
Extraction of murine bone marrow stroma cells 
All in vivo experiments were conducted in accordance with UK Home Office regulations 
(License P846C00DB). Murine bone marrow MSCs were established from femora and 
tibiae of 4 to 8 week-old mice. Bone marrow stroma cells were harvested from young 
female age-matched Prkcb+/+ and Prkcb−/− by flushing the cavities of femora and tibiae 
with PBS. After filtration through a 70-μm filter and depletion of erythrocytes using a lysis 
buffer (BD PharmLyse; BD Biosciences), washed cells were either used further for 
experiments or cryopreserved.  
 
Co-culture in vitro toxicity assay 
Malignant B cells from CLL, ALL, or MCL patients co-cultured on murine BMSCs, CD14+, 
or splenic follicular reticular cells (FRCs; gp38+CD31-) from PKC- WT or PKC- KO 
mice. Since PKC KO stroma grow marginally slower than WT, cell numbers were 
adjusted and BMSCs were seeded at equal concentrations of 2*104 cells per well of a 96-
well plate and incubated for 24 hours to allow for attachment. Subsequently, CLL, ALL, or 
MCL cells were seeded at 2*105 cells per well for monoculture and co-culture conditions 
and incubated for 24 hours. Enzastaurin (Sigma-Aldrich), sotrastaurin, bendamustine, 
idelalisib, midostaurin (Selleck Chemicals), venetoclax (LC Labs), fludarabine (Cayman 
Chemicals), ibrutinib (SYNkinase), dexamethasone, and vincristine sulfate (Sigma-
Aldrich) were added at specified concentrations and incubated for up to 48 hours, prior to 
flow cytometric analysis (representative gating depicted in fig. S11A). 
 
Generation of chimeric mice  
Bone marrow from CD45.2+ Prkcb+/+, Prkcb−/−, and CD45.1+ B6.SJL-Ptprca Pepcb/BoyJ 
(Jackson Laboratories) age-matched mice were isolated and depleted of CD45− cells 
with purity of >95% confirmed by flow cytometry (muCD45 microbeads; Miltenyi Biotec). 
3*106 cells of purified bone marrow of respective CD45.2+ Prkcb−/− purified-BM and 
CD45.1+ B6.SJL-Ptprca Pepcb/BoyJ purified-BM were injected intravenously into 
respectively different CD45 recipients, post-irradiation (10 Gy) (i.e. CD45.1+ BM into 
CD45.2 recipient and CD45.2+ BM into CD45.1 recipient). CD45.2+ Prkcb−/− BM was also 
injected into irradiated CD45.2+ Prkcb−/− recipients as a control (Fig. 2). Chimerism was 
assessed by flow cytometry of CD45.1 and CD45.2 staining of peripheral blood 
withdrawn by tail vein bleeding (representative gating depicted in fig. S11B). Serum 
immunoglobulin isotype levels were assessed from peripheral blood using a mouse 
specific immunoglobulin isotype panel and subsequently analyzed and quantified using 
commercial software (LegendPlex Mouse Ig Panel, LegendPlex Analysis Software; 
Biolegend). Peritoneal fluid, peripheral blood, bone marrow, and spleen were harvested 
from respective animals and analyzed by flow cytometry. Chimeric mice of appropriate 
genotype upon confirmation of chimerism were injected with 40*106 CFSE-labelled TCL1- 
tumor cells intravenously and 1*106 cells injected intraperitoneally. Assessment of 
labeled CLL cells in peripheral blood was performed by flow cytometry. 
 
Western blotting 
After the specified time CLL cells were lysed in RIPA buffer and a total of 15 µg protein 
was separated by SDS-polyacrylamide gel electrophoresis, blotted to polyvinylidene 
difluoride (PVDF) membranes (Millipore) and probed with primary antibodies against 
BCL-XL (Cell Signalling Technologies), BCL-2A1, -actin (both Sigma-Aldrich), NOXA, 
PUMA (both Abcam), BCL-2, BIM (both BD Biosciences), Mcl-1 (Santa Cruz 
Biotechnology). 
 
RNA-sequencing and data analysis 
CLL cells were cultured in mono-culture, or co-culture on murine BMSCs from WT or 
PKC- KO mice for 12 hours. Primary CLL cells were seeded at 6 x106 cells on the top of 
1 x 105 bone marrow MSCs per well of a 6 well plate. CLL cells were harvested for bulk 
RNA extraction and DNase treatment (RNA mini-prep kit, Sigma-Aldrich). Purity was 
confirmed by FACS analysis to be >95%. Human CLL cDNA libraries were prepared by 
using NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England 
Biolabs). Quality of cDNA libraries were determined using a Bioanalyzer High Sensitivity 
Chip (Agilent). Single-read sequencing was performed on the Illumina HiSeq 4000 
platform at the CRUK Cambridge Institute Genomic Core. Stromal cDNA libraries were 
similarly synthesized and analyzed. 
Sequencing data quality was assessed using the RSeQC package(60) and low quality 
reads and adapter sequences were removed using Trimgalore. Filtered data were 
aligned to the mm10 or hg38 reference genomes using RNA-STAR aligner(61) using the 
GENCODE Release 25 comprehensive GTF file with the following parameters: --
outSAMtype BAM SortedByCoordinate --sjdbGTFfile annotation.gtf  --outFilterType 
BySJout --outFilterMultimapNmax 50 --alignSJoverhangMin 1  --outFilterMismatchNmax 
2 --outFilterMismatchNoverLmax 0.04 --alignIntronMin 20  --alignIntronMax 1000000 --
alignMatesGapMax 1000000 --outSAMstrandField intronMotif. Quantification of gene 
expression was performed with HTSeq-0.11.0 (62) against the comprehensive gene 
annotation files from GENCODE (m14 and v25, for mouse and human genomes, 
respectively). Differential expression analysis was performed using DESeq2(63), 
controlling for differences between patient samples. To generate the heat-map shown in 
Fig. 3, a matrix of normalized counts was constructed using all differentially expressed 
genes (padj < 0.05; LFC >2) from pairwise comparisons between conditions (n=2,660 
genes) and k-means clustering of rows was performed (k=4). 
 
 
 
 
Multivariate analysis of clinical data 
For cross-validation of CLL-RNA sequencing analysis obtained (Fig. 3A-C, fig. S6A), we 
assessed the clinical impact of stromal PKC- dependent gene expression through data 
generated from PBMCs derived from a cohort of fludarabine-resistant CLL patients 
(n=51) subsequently treated with subcutaneous Alemtuzumab in a multicenter phase 2 
trial(23), (NCT00274976). Patient sampling was performed at enrollment and prior to 
Alemtzumab treatment. Profiled mRNA was extracted using the Allprep DNA/RNA mini kit 
(Qiagen) on PBMCs purified using ficoll density gradient centrifugation. Quality control on 
purity, concentration and RNA integrity was assessed using the Agilent 2100 Bioanalyzer 
with the RNA 6000 Nano LabChip (Agilent Technologies) and the 2100 Expert Software. 
Samples used had an RNA Integrity Number (RIN) ≥ 7.0. Affymetrix GeneChip® Human 
Exon 1.0 ST Array (Affymetrix) were used for expression profiling. Per sample, 250 ng 
RNA were amplified, transcribed to cDNA, fragmented and subsequently labeled with 
biotin. Array hybridization was performed at 45°C for 16-18h in the Affymetrix GeneChip 
Hybridization Oven 640, arrays were subsequently washed in the Fluidics Station 450 
and scanned with the GeneChip scanner 3000 7G. Experiments were conducted 
according to the manufacturer's protocol.   
 
Raw Affymetrix Human Exon array (HuEx-1_0-st-v2) data files were preprocessed by the 
robust multichip average (RMA) algorithm using Aroma. Affymetrix gene expression 
values were summarized on the transcript level using the ‘core’ probe set definition 
according to Affymetrix. The Genesis platform(64)  was used for clustering. Respective 
cluster and survival analysis was conducted only for genes impacting survival and 
showing co-expression. Hierarchical clustering was used with Manhattan distance and 
complete linkage. Clinical endpoints used for the survival analysis were progression-free 
survival (PFS) and overall survival (OS), data was missing in 2 patients.  
 
Plasma membrane profiling 
Plasma membrane profiling was performed as described previously (65). Peptides were 
subsequently labelled with TMT reagents (Thermo Fisher Scientific), pooled and cleaned 
up using a SEP-PAK C18 cartridge (Waters) prior to high pH RP fractionation as 
previously described(66). High pH fractions were pooled orthogonally into 12 samples for 
analysis by LC-MS on an Orbitrap Fusion (Thermo Fisher Scientific) utilising synchronous 
precursor selection mode to isolate reporter ions essentially as previously described(8). 
Data were searched using the MASCOT (Matrix Science, UK) search node within 
Proteome Discoverer v2.1 (Thermo Fisher Scientific). The database used was the 
SwissProt Mouse Reference Proteome including an appended database of common 
contaminants. Statistical differences between replicate groups were assessed using an 
implementation of LIMMA within the R environment including Benjamini-Hochberg 
correction for multiple hypothesis testing. The resulting p/q-values are reported. 
Experiment was performed in triplicate using one patient sample. For the heat-map 
shown in Fig. 5C, a matrix was constructed of the log2 transformed abundance values 
with the addition of a pseudo-count of 8 for all mid- to high-confidence protein 
measurements. This matrix was then used for k-means clustering (k=5) for each replicate 
across each condition. The side plot of the figure was generated using the median value 
of the abundance values for each replicate. The plot was generated using the seqsetvis 
R package (Boyd J (2018)) including Benjamini-Hochberg correction for multiple 
hypothesis testing.  
 
Flow cytometry  
All antibodies for flow cytometry measurements, as well as their respective isotype 
controls, were obtained either from BD Biosciences, Biolegend, eBioscience, Tonbo 
Biosciences, or Santa Cruz Biotechnology. For apoptosis analyses, FITC-Annexin V and 
DAPI (Biolegend) were used. A complete list of all antibodies used for this study can be 
found in the supplementary information (table S2). 
 
CRISPR/Cas9-mediated gene deletions 
Single-guide RNA (sgRNA) sequences were cloned into lentiCRISPRv2. Control_sgRNA 
(TCGGCACTGGCGATCGGTTG), Vcam1_sgRNA (GCTGGAACGAAGTATCCACG), 
Tfeb_sgRNA_1 (TGGACACGTACTGTCCACCT),  Tfeb_sgRNA_2 
(CTGTAGTTGAGAGAAGACGC), Tfeb_sgRNA_3 (TGAGATGCAGATGCCTAACA), 
Tfeb_sgRNA_4 (CCTCTGTGGATTACATCCGG). Lentiviral infections of murine bone 
marrow stromal cells with the specific sgRNA constructs were performed. Following 48 
hours of puromycin selection (2 μg/ml), cells were negatively sorted for Vcam1 
expression and cultured for further experiments, while Tfeb-deleted stroma were left 
unsorted after 72 hours of puromycin selection (2 μg/ml).  
 Neutralizing antibody assay 
Bone marrow MSCs were seeded at a concentration of 1*104 cells per well of a 96-well 
plate and incubated for 24 hours. Prior to addition of CLL cells 10mg/ml of neutralizing or 
control antibody, VCAM1 and Control Rat IgG2a (both Biolegend), was added for 1 
hour. CLL cells were then seeded at 2*105 cells per well for monoculture and co-culture 
conditions. Neutralizing antibodies were restored to 10 mg/ml following the addition of 
CLL cells. After 24 hours venetoclax was administered at 2.5 nM and incubated for a 
further 48 hours before flow cytometric analysis.  
 
Ibidi flow chamber cell adhesion assay  
Stromal cells of respective genotype, Prkcb+/+ and Prkcb−/−, were seeded at a 
concentration of 3*104 cells/100 l into the channel of Ibidi channel tissue-culture treated 
-slides (Ibidi; type 1, 0.4 mm). 12 hours later fresh media was added simultaneously to 
both reservoirs. Primary CFSE-labeled CLL cells were counted by two individuals using 
trypan blue staining. The average of both counts determined the respective seeding cell 
numbers of each patient. After simultaneous removal of all reservoir media from channel 
slides, 500 l of patient cell suspension was placed in one of the experiment-long 
designated influx reservoirs. Flow-through from atmospheric pressure into the efflux 
reservoir was reapplied to the designated influx reservoir 3 times for each slide. Final 
flow-through from efflux reservoirs were counted twice for each slide, averaged, and 
subtracted from respective seeding cell counts for each patient to obtain percent 
adhesion. Subsequently, 300 l of media was placed into both reservoirs simultaneously 
and incubated for 24 hours. Cells were then exposed to respective treatments after 
simultaneously withdrawal of culture media, and simultaneous application of treatment 
media. 48 hours later, flow-through using 500 l of fresh media placed into the 
designated influx reservoirs were performed 3 times using fresh media each flow-
through. Pass-throughs from the efflux reservoirs were collected and  
counted twice for cells, averaged and subtracted from each slide-specific number of 
adhered cells. 
 
 
Generation of Prkcb−/− stroma expressing constitutively active TFEB (caTFEB) 
Plasmids pCIP-caHuTFEB and empty vector pCIP (Plasmids #79013,79009; Addgene) 
were linearized using ScaI-HF restriction enzyme (New England Biolabs) (Young, NP 
2016), and subsequently purified using a NucleoSpin Gel Purification Kit (Machery-
Nagel). Transfections of a parental PKC- KO stroma were performed, using 5.0 g of 
each respective linearized plasmid prepared with Lipofectamine 2000 transfection 
reagent (ThermoFisher Scientific). 48 hours post-transfection, transfected cells and 
untransfected control were cultured in stromal media (MEM + 10% FBS +10% Horse 
Serum) containing 2 g/ml of puromycin for 72 hours (ThermoFisher Scientific).    
 
In vivo models for CLL homing and engraftment 
For CLL homing experiments primary E-TCL1 tumor cells were labelled with 5 M 
Carboxyfluorescein-succinimidyl-ester (CFSE; Life Technologies) per manufacturer’s 
protocol. Post-confirmation of labeling by flow cytometry, 40*106 cells were injected 
intravenously, and 1*106 cells injected intraperitoneally into age-matched mice of two 
genotypes. Peripheral blood was drawn by tail vein bleeding, and analyzed by flow 
cytometry following erythrocyte depletion. 
 
In vivo model for Vcam1 biomarker ± enzastaurin 
Leukemic E-TCL1 mice were analyzed for leukemic burden by CD5+C19+ staining of 
peripheral blood. Cohorts were assembled to match overall leukemic burden of vehicle 
control between enzastaurin treatment cohorts. Enzastaurin or vehicle (5% dextrose + 
10% ethanol in water), was administered at a dose of 60mg/kg BID for a total of 96 
hours. Analyses of bone marrow Vcam1 expression was conducted 3 hours following last 
treatment, by flow cytometry. In brief, stromal cell populations were isolated from femur 
and tibia, crushed in mortar and pestle, and digested with 2 ml of collagenase I (Stem 
Cell Technologies) and 1 mg/ml collagenase IV (Sigma-Aldrich,) at 37°C in strong 
agitation for 30 minutes. Cells were washed with PBS + 2% FBS and filtered through a 
40 m mesh filter. Red blood cells were lysed with Pharmalyse (BD Biosciences) for 10 
minutes on ice. Aliquots from individual mice were analysed by flow cytometry 
(representative gating depicted in fig. S11C). 
 
 In vivo model for Lamp-1 and Lamp-2 biomarkers ± enzastaurin 
72 hours post-transplantation TCL1-transplanted PKC- WT recipients were treated with 
either vehicle, venetoclax (100 mg/kg per day), or pre-treated with enzastaurin (60 mg/kg 
BID) and concomitantly administered with enzastaurin + venetoclax for the duration of 3 
days. Bone marrow was harvested 3 hours after administration of final dosing and 
subsequently analyzed for respective intracellular Lamp-1 and Lamp-2 expression after 
surface staining and subsequent fixation and permeabilization (Biolegend). Mean 
fluorescence intensities (MFIs) of Lamp-1 and Lamp-2 were assessed in viable MSCs 
(CD45-Ter119-) and non-MSCs (CD45+Ter119+). Statistical significance of intracellular 
staining was determined using an unpaired two-tail Student T-test. 
 
In vivo CLL study of venetoclax ± enzastaurin 
C57B/6J mice (Jackson Labs) were injected intraperitoneally with either 3.5*106 or 5*106 
cells of two respective primary E-TCL1 tumors. 72 hours post-transplantation respective 
treatments began by oral gavage for 16 consecutive days. Venetoclax was solubilized as 
previously reported (67). In brief, venetoclax was formulated in phosal-50 propylene 
glycol (60%), polyethyleneglycol-400 (30%), and ethanol (10%). Leukemic burden was 
assessed by erythrocyte-depleted peripheral blood analyzed by flow cytometry. 
 
In vivo CLL study of fludarabine ± enzastaurin 
C57B/6J (Jackson Labs, UK) mice were injected intraperitoneally with 5*106 cells of two 
respective primary E-TCL1 tumors. 72 hours post-transplantation mice respective 
treatments began by oral gavage and intraperitoneal injection. Fludarabine phosphate 
(Sigma-Aldrich) was solubilized in sterile PBS.  Mice received Fludarabine treatment for 5 
consecutive days for two cycles. Enzastaurin or vehicle was administered twice daily of 
the same periods. Leukemic burden was assessed by peripheral blood analyzed by flow 
cytometry. 
 
In vivo ALL-PDX study of vincristine ± enzastaurin 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were injected intravenously with 2-3*105 cells 
of luciferase-transduced ALL xenografts cells derived from 2 unique patient samples. In 3 
independent experiments, cohorts were respectively treated 72 hours post-
transplantation. enzastaurin (60mg/kg BID) or vehicle control was administered orally, 12 
hours prior to intraperitoneal dosing of vincristine or vehicle and continued for 72 hours 
thereafter. Vincristine (Sigma-Aldrich) was solubilized in sterile PBS and administered 
once per treatment cycle at a weight-adjusted dose between 0.5 mg/kg and 0.6 mg/kg 
(68). Animals received equal treatment dosages between treated cohorts for each 
independent experiment, for one or two cycles. For the combination treated cohorts, 14 
mice received one-cycle, whereas 5 mice received a second treatment cycle 4 weeks 
following initial treatment. Anesthesia-related morbidities on Day 73 post-transplantation 
in one independent experiment resulted in the censoring of 3 (vincristine) and 4 
(combination treatment) animals. Leukemic burden was assessed by peripheral blood, 
which was analyzed by flow cytometry and by bioluminescent imaging (Xenogen IVIS). 
Luciferin was administered intraperitoneally to anesthetized animals prior to live imaging. 
 
Statistical analysis 
Statistical analyses of results were performed using one-way ANOVA followed by two-tail 
Student t-tests, with respective unpaired and paired analyses experimentally dependent. 
Statistical annotations as previously noted were denoted with asterisks according to the 
following, **** p < 0.0001, *** p <0.001, ** p <0.01, * p<0.05, and ns p >0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. Homing and engraftment kinetics of E-TCL1 tumor cells in PKC-wild-type and null mice. (A) An 
experimental scheme to assess homing of E-TCL1 cells in PKC- WT and KO mice, respectively. (B) Representative 
CD19
+
 FACS plots of four tissue compartments, 48 hours post-transplantation of CFSE-labeled E-TCL1 cells. (C) 
Homing of CFSE-labelled E-TCL1 cells was quantified as a percentage of total CD19
+
 cells ±SEM. (D) Quantification of 
CFSE-labelled E-TCL1 cells as a percentage total CD19
+
 cells detected in the peripheral blood at indicated time-points 
(Day1: WT, n=5; KO, n=8; Day 2: WT, n=3; KO, n=4; Days 8-14: WT, n=6; KO, n=8). Analyses are pooled from 
independent experiments using two primary tumors. (E) Representative FACS plots of bone marrow, spleen, and 
peritoneal cavity on day 2 and day 14 post-transplantation of CFSE-labeled E-TCL1 cells, respectively.  
 
 
 
 
Fig. S2. PKC-deficiency does not overtly alter hematopoiesis. (A) White blood cell (WBC), red blood cell (RBC), 
and platelet (PLT) abundance are shown from complete blood counts of peripheral blood from age-matched PKC- WT 
and KO mice. (B) Individual abundance of white blood cell types is graphically shown. (C) Bone marrow composition of 
Lin
-
Sca1
+
C-Kit
+
 (LSK) and CD150
+
CD48
-
CD45
+
EPCR
+
 (ESLAM) hematopoietic stem cells are shown as a percentage of 
CD150
+
CD48
-
 cells. (D) Representative gating strategy of bone marrow B-cell progenitors. (E) Composition of B-cell 
progenitor fractions (Hardy fractions) are shown as a percentage of B220
+
CD43
+ 
(left axis, Fraction A-C’) and of 
B220
+
CD43
-
 (right axis, Fraction D-F). (F) Absolute numbers of B-cell progenitor fractions (Hardy fractions) are shown as 
a total of RBC-lysed bone marrow from a respective femur of PKC- WT (n=4) and KO (n=4) mice (left axis, Fractions A-
C’; right axis, Fraction D-F). 
  
 
 
 
Fig. S3. PKC- chimeras engraft with comparable efficiency irrespective of donor or recipient genotype. (A) 
Representative CD45.1 and CD45.2 FACS plot stains of peripheral blood, 8 weeks post-transplantation, are shown with 
the donor label and percentage of donor cells denoted in bold. (B) Representative CD5 and IgM FACS plots for CD19
+
 
cells of the peritoneal cavity are shown for the similarly labeled cohorts as above in fig. S3A. (C) Assessment of 
chimerism in mice with mismatched CD45 isotypes. Percentages of respective donor CD45 isotype are shown ±SEM. 
Genotype of donor BM is set in bold; WT:WT (n=3), KO:WT (n=4), and WT:KO (n=4; n=3 for PB CD45
+
 and BM 
CD138
+
). Abbreviations for tissues as follows: PB, peripheral blood; PC, peritoneal cavity; SPC, splenocytes; BM, bone 
marrow. Ten weeks post transplantation, a mixed chimerism was observed in the peripheral blood with a predominance 
of the transplanted bone marrow cells (WT(donor):WT(recipient)=72.0% ±2.09%, WT:KO=73.7 ±7.11%, KO:WT=64.1% 
±1.13%. (D) Representative CD45.1
+
 and CD45.2
+
 stains of respective CD138
-
 and CD138
+
 BM or splenic cells are 
shown. Ratios of donor : recipient are indicated within respective stains. (E) Graphs of percent donor BM CD45
+
CD138
-
 
cells and percent donor BM CD45
+
CD138
+
 cells are plotted, with equal donor engraftment of both ±CD138 
compartments depicted by the dotted line. Percentages of donor cells are shown as a subset of total CD45
+
 cells. (F) 
Graphs of splenic donor CD45
+
CD138
-
 engraftment and splenic donor CD45
+
CD138
+
 engraftment are plotted. 
Percentages of donor cells reflect the percent of total CD45
+
 cells.   
  
Fig. S4. Monocytes confer CLL survival support but not PKC- dependent EMDR, in contrast to MSCs. (A) 
Representative flow cytometry plots of cytokine-naive PKC- WT, and M-CSF cultured PKC- WT and PKC- KO 
stroma. (B) Representative Annexin-V and DAPI flow cytometry plots of mono-cultured or respective co-cultured CLL 
cells, 72 hours post-seeding of CLL. (C) Percentage of Live (Annexin-V
-
, DAPI
+
), Annexin-V
+
, and Dead (DAPI
+
Annexin-
V
+or -
) stained cells are shown for individually co-cultured primary CLL (n=5 unique patients) for the three respective 
conditions. Statistical comparisons are shown for the live-cell fractions of each condition. (D) Viability of CLL cells 
following 72 hours of respective co-culture (CD14
+
 PKC- WT or CD14
+ 
PKC- KO cells) with 48 hours of exposure to 
increasing doses of venetoclax (n=6). (E) Representative Annexin-V and DAPI flow cytometry plots of mono-cultured or 
respective co-cultured CLL cells, 72 hours post-seeding of CLL. (F) Viability of CLL cells following 72 hours of PKC- WT 
co-culture with 48 hours of exposure to increasing doses of respective bendamustine (n=8), ibrutinib (n=9), or idelalisib 
(n=7) ± enzastaurin treatment. Statistical significance was assessed using a paired two-tail Student-T-test. (G) 
Synergism was calculated using Combenefit Software (CRUK), within the Loewe additivity model, for venetoclax 
combined with enzastaurin, sotrastaurin, or midostaurin, respectively (n=6 per combination). 
 
       
 
 
Fig. S5. PKC--mediated EMDR involves increased protein levels of BCL-XL. (A) Graphs of respective BCL-XL 
(n=5), BCL-2 (n=5), MCL-1 (n=3) fold protein levels in CLL cells co-cultured with either PKC- WT or PKC- KO, relative 
to -Actin after indicated exposures to 2.5 nM venetoclax. (B)  Quantitative-PCR measured relative BCL-XL expression in 
CLL (n=4) in the respective presence of PKC- WT or KO stromal co-culture (2
-∆∆CT
). (C) Quantitative-PCR measured 
relative BCL-XL expression in CLL (n=6) co-cultured with PKC- WT ± venetoclax treatment (2.5 nM) for the indicated 
timepoints. 
  
 
 
 
Fig. S6. CLL signaling pathways regulated by stromal PKC- correlate with clinical outcomes. (A) IPA analysis of 
canonical pathways activated in CLL cells (n=3) co-cultured with PKC- WT stroma compared to CLL cells co-cultured 
with PKC- KO stroma (n=3), both in the presence of venetoclax (1.25 nM). (B) Graph of p-ERK (n=4) fold protein levels 
in CLL cells co-cultured with either PKC- WT or PKC- KO, relative to total ERK after indicated exposures to 2.5 nM 
venetoclax. (C) BCL-XL, phosphorylated ERK (Thr202/Thr204), total ERK and -actin immunoblots of primary CLL at 
indicated time-points of venetoclax treatment, co-cultured with PKC- WT stroma ± enzastaurin (5 M). (D, related to 
Fig. 3I) Graphs of respective phosphorylated-AKT relative fold protein levels in CLL cells co-cultured with either PKC- 
WT or PKC- KO after indicated exposures to 2.5 nM venetoclax. (E, related to Fig. 3K) Kaplan-Meier curves (x-axis 
with time since treatment) according to respective clusters (”High co-expression” vs. “Low co-expression”), showing 
statistically significant differences (pairwise log-rank tests) for median progression-free survival (PFS) (”High co-
expression”: 122 days vs “Low co-expression”: 440 days; p<0.02). 
 
 
 
 
  
Fig. S7. Stromal lysosomes, and lysosomal biogenesis regulator TFEB, are central to PKC--mediated EMDR. (A) 
Lysosomal staining using Lysotracker Red (50 nM for 30 mins) of passage-matched naive PKC- WT stroma and PKC- 
KO stroma, respectively ± chloroquine (50 mM for 1hr), and co-cultured stroma of both PKC- genotypes ±venetoclax 
(2.5 nM). (B, related to Fig. 4E) Analysis of stromal optical density of nuclear TFEB/TBP ratios for indicated PKC- WT 
and KO stroma (CLL co-cultures denoted by solid symbols and naive stroma denoted by open symbols). Statistical 
significance assessed using two-tailed ratio-paired t-test. (C) CLL viability assay (n=5) co-cultured on stroma 12 hours 
after pre-treatment with enzastaurin, chloroquine, or bafilomycin for 6 hours followed by washout prior to CLL-seeding. 
Venetoclax treatment was applied in noted conditions 24 hours post CLL-seeding. (D) Representative FACS plots of CLL 
cells from mono-cultured or respective co-cultured CLL cells, 72 hours post-seeding and 48 hours post-treatment of CLL. 
(E) In vitro downregulation of Vcam1 in PKC- WT stroma co-cultured with CLL ±increasing concentrations of 
enzastaurin. (F, related to Fig. 5H) Graph of CD106 (Vcam1) MFIs from mono-cultured PKC- WT stroma with Crispr-
deleted cells transduced with sgRNA control (n=3) or Tfeb-deleted stroma using 4 unique sgRNAs, respectively (n=8 
total values; duplicate measurements for n=4 sgRNAs). 
  
 
 
 
 
Fig. S8. PKC- is dispensable for in vitro and in vivo mobilization of leukemia. (A) Schematic of adhesion and 
mobilization assays utilizing channel slides. (B, related to Fig. 5K) Representative flow cytometry plots of CD19
+
CD5
+
 
cells in the peripheral blood before and during treatment with enzastaurin or vehicle, respectively. (C, related to Fig. 5L) 
Representative flow cytometry plots of CD19
+
CD5
+
 cells in the bone marrow, spleen, and peritoneal cavity after 
treatment with enzastaurin or vehicle, respectively. 
 
 
 
 
Fig. S9. In vivo co-targeting of PKC- does not contribute to increased off-target cytotoxicity. (A) In vivo treatment 
schematic of E-TCL1 CLL model using venetoclax, enzastaurin, mock control or venetoclax + enzastaurin. (B) 
Complete blood counts (CBC) of non-leukemic WT control (n=2), vehicle control (n=4), enzastaurin-treated (n=4), 
venetoclax-treated (n=4), and enzastaurin + venetoclax treated (n=4) mice on Day 32 post-end of treatment. Normal 
blood counts are indicated between dashed lines. Statistical differences were calculated by unpaired Student T-Test. (C) 
Photographs at week 12 post-treatment of representative mice from vehicle, venetoclax, and enzastaurin + venetoclax 
treatment cohorts. (D) Terminal spleen weights for individuals of indicated treatment cohorts. (E)  Schematic of in vivo 
treatment model of E-TCL1 CLL using fludarabine + vehicle or fludarabine + enzastaurin. (F) Percentage of detectable 
peripheral blood CD5
+
CD19
+
 cells in non-leukemic controls (n=3), fludarabine-treated (n=3) and fludarabine + 
enzastaurin treated mice (n=4), on days 25 - 28 post-end of first treatment cycle. (G) Complete blood counts of non-
leukemic WT control (n=2), vehicle control (n=3), fludarabine-treated (n=3), and enzastaurin + fludarabine treated (n=3) 
mice on Day 16 post-end of first-treatment cycle. (H) Complete blood counts of non-leukemic WT control (n=1), vehicle 
control (n=2), fludarabine-treated (n=3), and enzastaurin + fludarabine-treated (n=3) mice on Day 10 post-end of second-
treatment cycle. (I)  TCL1-HG cells were transplanted into either PKC- WT (MST= 31 days) or PKC- KO recipients 
(MST= 76 days). (J) Average radiance obtained by bioluminescent imaging of ALL-PDX engrafted NSG animals treated 
with either vehicle control or enzastaurin. Statistical significance was determined using an unpaired two-tail Student T-
test. 
  
  
 
 
Fig. S10. EMDR derived from splenic stroma is mitigated by PKC- antagonism. (A) In vitro treatment of primary 
CLL (n=10) in monoculture or co-culture on splenic FRC stroma (gp38
+
CD31
-
) treated with either vehicle control, 
enzastaurin, venetoclax, or venetoclax + enzastaurin. Statistical significance was determined using a paired two-tail 
Student T-test. 
 
Fig. S11. Representative FACS gating strategies. (A) Representative FACS gating for co-culture in vitro cytotoxicity 
assays (left to right). (B) FACS gating strategy for immunophenotyping of peritoneal cells from chimeric mice (left to right, 
per row). (C) Representative FACS gating strategy for in vivo HSC phenotyping (left to right, per row). 
 
  
 Supplemental Table S1: Patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
   
    * UM/MIGVH=unmutated/ mutated IGVH 
       IHC=immunohistochemistry 
       FC=flow cytometry 
Chronic lymphocytic leukemia (Figures 2-5,S4-S7,S9-S11) 
Encrypted 
Patient ID 
Cytogenetic results/ 
IGVH-status* 
Live cell decrease 
w/enzastaurin + venetoclax 
(5 nM) vs. venetoclax  
alone 
Live cell decrease 
w/enzastaurin +fludarabine 
(2.5 uM) vs. fludarabine  
alone 
BP0401 Del13q14, M-IGVH 57.9% 40.8% 
BS4072 Del13q14, UM-IGVH -0.8% 37.9% 
CL9959 Data not available 45.8% 28.5% 
DP3335 Del13q14, M-IGVH 48.4% 19.2% 
KA9559 Negative FISH panel 26.4% 14.2% 
DI7353 Del13q 55.7% -1.9% 
BF59 Del13q, Del17p 51.3% -3.7% 
JC2614 
Normal FISH panel,  
UM-IGVH 
69.4% 5.8% 
SJ35 Data not available 80.8% 25.1% 
MB6377 Del17p 23.8% 24.4% 
MO2147 P53 mutated 41.9% 56.5% 
EB5492 Trisomy12 14.7% 2.3% 
CH8051 Del17p 33.4% -1.9% 
EG5792 Trisomy12 25.6% 18.9% 
AR30 Del13q, Del11q 27.4% 16.8% 
AS5041 Del13q, Del17p, Del11q 40.4% -3.1% 
JC833 Del13q, Del11p 16.7% 21.8% 
SM7753 Del13q, Del17p, Trisomy12 27.2% -3.8% 
PF8841 Del17p, Trisomy13q14 37.5% 37.0% 
DW5916 Trisomy 12 19.1% 13.0% 
Mantle Cell Lymphoma (Figure 6F) 
Encrypted 
Patient ID 
Cytogenetic results/ IHC/FC 
Live cell decrease 
w/enzastaurin + venetoclax 
(2.5 nM) vs. venetoclax  
alone 
Live cell decrease 
w/enzastuarin + venetoclax 
(5 nM) vs. venetoclax  
alone 
12414 t(11;14), Cyclin D1+ 19.6% 25.8% 
10084 t(11;14), Cyclin D1+ 40.4% 34.0% 
12267 t(11;14), Cyclin D1+ 40.9% 46.8% 
FC0175 
 
CD19
+
, CD20
+
, CD79b
+
 
CD5
+
, CD200
- 
(FISH unavailable) 
 
43.9% 41.7% 
PG220 Data not available 47.1% 38.9% 
V314 Blastoid MCL, Cyclin D1+ 3.8% 1.8% 
V323 
t(11;14), monosomy 12 
Cyclin D1+, p53 Del 
39.2% 27.1% 
M13 CD5+, PAX5+, FCM7++ 9.5% 6.8% 
B-Acute lymphoblastic leukemia (Figure 6G,H) 
Encrypted 
Patient ID 
Cytogenetic results 
Live cell decrease 
w/enzastaurin + 
dexamethasone 
(0.1 nM) vs. dexamethasone  
alone 
Live cell decrease 
w/enzastaurin + vincristine 
(50 nM) vs. vincristine 
 alone 
190615A Complex Karyotype 81.4% 57.8% 
310315A MLL-AF9 - 47.1% 
201115A TEL-AML1 15.3% 39.7% 
260416A TEL-AML1 76.3% 33.5% 
261215A TEL-AML1 70.0% 42.6% 
170815A E2A-PBX1 41.3% 34.9% 
080915A Hyperdyploid 18.4% 13.3% 
130516A TEL-AML1 15.0% 43.3% 
131015A High-Hyperdyploid 56.6% 13.3% 
170816A High-Hyperdyploid 21.1% 11.4% 
Supplemental Table S2: Key resources 
 
Antibodies Source Catalog # 
Anti-Human FcR (1:200 dilution) Biolegend 422302 
Anti- Mouse FcR (1:200 dilution) Biolegend 101320 
Anti-Mouse CD45.1 (A20)–FITC (1:200 dilution) Tonbo Bioscience 35-0453-U500 
Anti-Mouse CD45.2 (104)–APC (1:200 dilution) Biolegend 109814 
Anti-Mouse CD45.1 - PerCP/Cy5.5 (1:200 dilution) Biolegend 110728 
Anti-Human CD19 - APC (1:200 dilution) Biolegend 302212 
Anti-IgM-FITC (1:200 dilution) Biolegend 406506 
Anti-Mouse CD138-BV421 (1:200 dilution) Biolegend 142523 
Anti-Mouse CD19-BV421 (1:200 dilution) Biolegend 302233 
Anti-Mouse CD5-APC (1:200 dilution) Biolegend 100626 
Anti-Mouse CD19-FITC (1:200 dilution) Biolegend 101505 
Anti-Mouse CD19-APC (1:200 dilution) Biolegend 115112 
Anti-Mouse CD106-APC (1:200 dilution) Biolegend 105717 
Anti-Mouse B220-BV421 (RA3-6B2) (1:100 dilution) Biolegend 103239 
Anti-Mouse CD24-BV605 (MI/69) (1:100 dilution) Biolegend 101827 
Anti-Mouse IgD-FITC (11-26c.2a) (1:100 dilution) Biolegend 405704 
Anti-Mouse CD43-APC (S7) (1:100 dilution) Becton Dickinson Biosciences 560663 
Anti-Mouse CD249-PE(6C3) (1:100 dilution) eBioscience 12-5891-81 
Anti-Mouse IgM-PerCPe710 (II/41) (1:100 dilution) eBioscience 46-5790-82 
Anti-Mouse Ter119-PeCy7 (1:200 dilution) Becton Dickinson Biosciences 557853 
Anti-Mouse CD45-PeCy7 (1:400 dilution) eBioscience 25-0451-82 
Anti-Mouse CD31-APC (1:100 dilution) Becton Dickinson Biosciences 551262 
Anti-Mouse CD51-BV (1:100 dilution) Becton Dickinson Biosciences 740062 
Anti-Mouse Sca-1-APCCy7 (1:100 dilution) Becton Dickinson Biosciences 560654 
Anti-Mouse CD14-FITC (1:200 dilution) Biolegend 123311 
Anti-Mouse/Human CD45R/B220-FITC (1:200 dilution) Biolegend 103206 
Anti-Human CD5-FITC (1:100 dilution) Becton Dickinson Biosciences 555352 
Anti-Human CD19-APC (1:100 dilution) Becton Dickinson Biosciences 555415 
Anti-Human CD19-BV421(HIB19) (1:100 dilution) Biolegend 302233 
Anti-Human TFEB (1:500 dilution) Cell Signaling Technology 37785S 
Anti-Human TBP (1:1000 dilution) Cell Signaling Technology 8515S 
Anti-Human BCL-XL (1:1000 dilution) Cell Signaling Technology 54H6 
Anti-Human BCL-2 (1:1000 dilution) Becton Dickinson Biosciences 610539 
Anti-Human MCL-1 (1:500 dilution) Santa Cruz Biotech SC-819 
Anti-Human BCL-2A1 (1:1000 dilution) Sigma-Aldrich AV09047 
Anti-Human NOXA (1:500 dilution) Abcam ab140129 
Anti-Human PUMA (1:500 dilution) Abcam ab33906 
Anti-Human BIM (1:500 dilution) Becton Dickinson Biosciences 559685 
Anti-Human p-ERK (1:1000 dilution) Cell Signaling Technology 4370s 
Anti-Human ERK (1:1000 dilution) Cell Signaling Technology 9102s 
Anti-Human p-JNK (1:1000 dilution) Cell Signaling Technology 9251s 
Anti-Human p-p38MAPK (1:1000 dilution) Cell Signaling Technology 9211s 
Anti-Human LAMP1 (1:1000 dilution) Cell Signaling Technology 9091s 
P-p42/44 MAPK (1:500 dilution) Cell Signaling Technology 9101s 
Anti-Actin (1:5000 dilution) Sigma-Aldrich A5441-.2ML 
Anti-Mouse Lamp1–PE (1D4B) (1:100 dilution) Santa Cruz Biotech sc-19992-PE 
Anti-Mouse Lamp2–Alexa488 (M3/84) (1:100 dilution) Biolegend 108510 
Biological Samples Source Catalog # 
CLL Patient Samples (Project ID: 07/MRE05/44) 
Cambridge University Hospitals - 
Addenbrookes 
N/A 
MCL Patient Samples (Project ID: 1894/07) Technical University Munich N/A 
Patient-derived xenografts (Erasmus IRB) University College London N/A 
Murine stromal cells This paper N/A 
Chemical Compounds Source Catalog # 
Zombie Aqua - BV510 (1:2000 dilution) Biolegend 423101 
Annexin-V FITC (1:50 dilution) Biolegend 640945 
DAPI (3 M) Biolegend 422801 
Enzastaurin Sigma-Aldrich SML0762  
Sotrastaurin Selleck Chemicals S2791 
Bendamustine Selleck Chemicals S1212 
Idelalisib Selleck Chemicals S2226 
Midostaurin Selleck Chemicals S8064 
Venetoclax LC Labs v-3579 
Fludarabine Cayman Chemicals 14128 
Ibrutinib SYNKinase SYN-1171 
Dexamethasone Sigma-Aldrich D4902 
Vincristine Sulfate Sigma-Aldrich V8879 
Critical Commercial Assays Source Catalog # 
LEGENDplex Mouse Immunoglobulin Isotyping Panel Biolegend 740492 
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